BioRestorative Therapies (BRTX) 10-Q 14 Aug 14 2014 Q2 Quarterly report Financial data

Document_And_Entity_Informatio

Document And Entity Information	6 Months Ended
	Jun. 30, 2014	Aug. 08, 2014
Document Information [Line Items]	'	'
Document Type	'10-Q	'
Amendment Flag	'false	'
Document Period End Date	30-Jun-14	'
Document Fiscal Year Focus	'2014	'
Document Fiscal Period Focus	'Q2	'
Entity Registrant Name	'BioRestorative Therapies, Inc.	'
Entity Central Index Key	'0001505497	'
Current Fiscal Year End Date	'--12-31	'
Entity Filer Category	'Smaller Reporting Company	'
Trading Symbol	'BRTX	'
Entity Common Stock, Shares Outstanding	'	26,803,355

Condensed_Consolidated_Balance

Condensed Consolidated Balance Sheets (USD $)	Jun. 30, 2014	Dec. 31, 2013
Current Assets:	'	'
Cash	$59,163	$201,098
Inventories	17,790	17,965
Prepaid expenses and other current assets	18,091	20,739
Total Current Assets	95,044	239,802
Property and equipment, net	18,347	35,568
Intangible assets, net	1,072,638	1,107,545
Total Assets	1,186,029	1,382,915
Current Liabilities:	'	'
Accounts payable	893,423	1,269,970
Accrued expenses and other current liabilities	1,155,966	1,176,662
Accrued interest	78,230	65,909
Current portion of notes payable, net of debt discount of $47,506 and $237,381 at June 30, 2014 and December 31, 2013, respectively	5,905,552	4,990,009
Deferred revenues	224,975	0
Total Current Liabilities	8,258,146	7,502,550
Accrued interest, non-current portion	0	41,434
Notes payable, non-current portion, net of debt discount of $0 and $3,110 at June 30, 2014 and December 31, 2013, respectively	76,669	524,000
Total Liabilities	8,334,815	8,067,984
Commitments and contingencies	'	'
Stockholders' Deficiency:	'	'
Preferred stock, $0.01 par value; Authorized, 1,000,000 shares; none issued and outstanding at June 30, 2014 and December 31, 2013	0	0
Common stock, $0.001 par value; Authorized, 100,000,000 shares; Issued 25,573,865 and 19,633,173 shares at June 30, 2014 and December 31, 2013, respectively; Outstanding 25,015,244 and 19,074,552 shares at June 30, 2014 and December 31, 2013, respectively	25,574	19,633
Additional paid-in capital	15,672,869	13,139,712
Accumulated deficit	-22,815,229	-19,812,414
Treasury stock, at cost, 558,621 shares at June 30, 2014 and December 31, 2013	-32,000	-32,000
Total Stockholders' Deficiency	-7,148,786	-6,685,069
Total Liabilities and Stockholders' Deficiency	$1,186,029	$1,382,915

Condensed_Consolidated_Balance1

Condensed Consolidated Balance Sheets (Parenthetical) (USD $)	Jun. 30, 2014	Dec. 31, 2013
Current portion of notes payable, debt discount	$47,506	$237,381
Non-current portion of notes payable, debt discount	$0	$3,110
Preferred stock, par value	$0.01	$0.01
Preferred stock, Authorized	1,000,000	1,000,000
Preferred stock, issued	0	0
Preferred stock, outstanding	0	0
Common stock, par value	$0.00	$0.00
Common stock, Authorized	100,000,000	100,000,000
Common stock, Issued	25,573,865	19,633,173
Common stock, Outstanding	25,015,244	19,074,552
Treasury stock, at cost, shares	558,621	558,621

Condensed_Consolidated_Stateme

Condensed Consolidated Statements of Operations (USD $)	3 Months Ended		6 Months Ended
	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013
Revenues	$175,941	$425	$176,316	$1,555
Cost of sales	42,366	36	42,426	198
Gross Profit	133,575	389	133,890	1,357
Operating Expenses	'	'	'	'
Marketing and promotion	15,535	35,711	47,329	65,592
Consulting	557,565	140,389	824,763	370,505
Research and development	293,330	372,916	787,071	773,358
General and administrative	548,632	565,251	1,184,632	1,205,361
Total Operating Expenses	1,415,062	1,114,267	2,843,795	2,414,816
Loss From Operations	-1,281,487	-1,113,878	-2,709,905	-2,413,459
Other (Expense) Income	'	'	'	'
Interest expense	-72,390	-32,035	-145,521	-229,903
Amortization of debt discount	-145,930	-105,282	-244,435	-166,631
Loss on extinguishment of notes payable, net	0	0	-49,094	-7,200
Warrant modification expense	0	0	-30,128	0
Gain on settlement of payables	166,668	0	176,268	0
Total Other Expense	-51,652	-137,317	-292,910	-403,734
Net Loss	($1,333,139)	($1,251,195)	($3,002,815)	($2,817,193)
Net Loss Per Share - Basic and Diluted	($0.06)	($0.08)	($0.14)	($0.18)
Weighted Average Number of Common Shares Outstanding - Basic and Diluted	22,852,110	16,502,710	21,552,120	15,908,635

Condensed_Consolidated_Stateme1

Condensed Consolidated Statement of Changes in Stockholders' Equity (Deficiency) (USD $)

Total

Cash

Shares issued for consulting services

Shares and warrants issued in exchange of notes payable and accrued interest

Common Stock

Common Stock

Common Stock

Common Stock

Additional paid-in capital

Additional paid-in capital

Additional paid-in capital

Additional paid-in capital

Deficit accumulated during development stage

Deficit accumulated during development stage

Deficit accumulated during development stage

Deficit accumulated during development stage

Treasury Stock

Treasury Stock

Treasury Stock

Treasury Stock

Cash

Shares issued for consulting services

Shares and warrants issued in exchange of notes payable and accrued interest

Cash

Shares issued for consulting services

Shares and warrants issued in exchange of notes payable and accrued interest

Cash

Shares issued for consulting services

Shares and warrants issued in exchange of notes payable and accrued interest

Cash

Shares issued for consulting services

Shares and warrants issued in exchange of notes payable and accrued interest

Beginning Balance at Dec. 31, 2013

($6,685,069)

'

'

'

$19,633

'

'

'

$13,139,712

'

'

'

($19,812,414)

'

'

'

($32,000)

'

'

'

Beginning Balance (in shares) at Dec. 31, 2013

'

'

'

'

19,633,173

'

'

'

'

'

'

'

'

'

'

'

-558,621

'

'

'

Share issued

15,000

945,000

240,398

343,026

0

2,969

878

1,101

15,000

942,031

239,520

341,925

0

0

0

0

0

0

0

0

Share issued (in shares)

'

'

'

'

'

2,968,651

878,458

1,101,453

'

'

'

'

'

'

'

'

0

0

0

0

Exercise of warrants into common stock

80,000

'

'

'

267

'

'

'

79,733

'

'

'

0

'

'

'

0

'

'

'

Exercise of warrants into common stock (in shares)

'

'

'

'

266,667

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

Conversion of notes payable and accrued interest into common stock

166,768

'

'

'

726

'

'

'

166,042

'

'

'

0

'

'

'

0

'

'

'

Conversion of notes payable and accrued interest into common stock (in shares)

'

'

'

'

725,463

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

Warrant modification

30,128

'

'

'

0

'

'

'

30,128

'

'

'

0

'

'

'

0

'

'

'

Beneficial conversion features associated with convertible notes payable

41,384

'

'

'

0

'

'

'

41,384

'

'

'

0

'

'

'

0

'

'

'

Stock-based compensation

677,394

'

'

'

0

'

'

'

677,394

'

'

'

0

'

'

'

0

'

'

'

Net loss

-3,002,815

'

'

'

0

'

'

'

0

'

'

'

-3,002,815

'

'

'

0

'

'

'

Ending Balance at Jun. 30, 2014

($7,148,786)

'

'

'

$25,574

'

'

'

$15,672,869

'

'

'

($22,815,229)

'

'

'

($32,000)

'

'

'

Ending Balance (in shares) at Jun. 30, 2014

'

'

'

'

25,573,865

'

'

'

'

'

'

'

'

'

'

'

-558,621

'

'

'

Condensed_Consolidated_Stateme2

Condensed Consolidated Statements of Cash Flows (USD $)	6 Months Ended
	Jun. 30, 2014	Jun. 30, 2013
Cash Flows From Operating Activities	'	'
Net loss	($3,002,815)	($2,817,193)
Adjustments to reconcile net loss to net cash used in operating activities:	'	'
Amortization of debt discount	244,435	166,631
Depreciation and amortization	50,139	53,105
Loss on sale of property and equipment	1,009	0
Stock-based compensation	917,792	369,868
Loss on extinguishment of note and payables, net	49,094	7,200
Gain on settlement of payables	-176,268	0
Warrant modification expense	30,128	0
Changes in operating assets and liabilities:	'	'
Inventories	175	-1,302
Prepaid expenses and other current assets	2,648	-33,872
Accounts payable	-369,047	231,614
Accrued interest, expenses and other current liabilities	267,810	549,690
Deferred revenues	224,975	0
Total Adjustments	1,242,890	1,342,934
Net Cash Used in Operating Activities	-1,759,925	-1,474,259
Cash Flows From Investing Activities	'	'
Proceeds from sale of property and equipment	980	0
Net Cash Provided by Investing Activities	980	0
Cash Flows From Financing Activities	'	'
Proceeds from notes payable	670,000	563,000
Repayments of notes payable	-53,000	0
Advances from director and officer	15,015	75,385
Repayment of advances from director and officer	-40,005	-69,370
Proceeds from exercise of warrants	80,000	0
Sales of common stock and warrants for cash	945,000	905,000
Net Cash Provided by Financing Activities	1,617,010	1,474,015
Net Decrease In Cash	-141,935	-244
Cash - Beginning	201,098	363
Cash - Ending	59,163	119
Cash paid during the period for:	'	'
Interest	43,821	29,101
Non-cash investing and financing activities:	'	'
Shares and warrants issued in exchange for notes payable and accrued interest	343,026	247,047
Conversion of notes payable and accrued interest into common stock	166,768	0
Accrued interest reclassified as principal in connection with note payable reissuance	73,058	53,100
Beneficial conversion features set up as debt discount	41,384	0
Shares Issued in Satisfaction of Accrued Interest	'	'
Non-cash investing and financing activities:	'	'
Shares issued	0	213,000
Shares and warrants issued in connection with issuance or extension of notes payable	'	'
Non-cash investing and financing activities:	'	'
Shares issued	$15,000	$488,325

Business_Organization_Nature_o

Business Organization, Nature of Operations, and Basis of Presentation	6 Months Ended
	Jun. 30, 2014
Organization, Consolidation and Presentation Of Financial Statements [Abstract]	'
Business Organization, Nature of Operations, and Basis of Presentation	'
	Note 1 – Business Organization, Nature of Operations, and Basis of Presentation
	BioRestorative Therapies, Inc. (and including its subsidiaries, “BRT” or the “Company”) develops medical procedures using cell and tissue protocols, primarily involving adult stem cells designed for patients to undergo minimally invasive cellular-based treatments. BRT’s website is at www.biorestorative.com. BRT’s “brtxDISC™ Program” (Disc Implanted Stem Cells) is designed to offer a non-surgical cellular therapy for the treatment and relief of protruding, bulging and herniated discs. BRT’s “ThermoStem® Program” (Brown Fat Stem Cells) focuses on treatments for metabolic disorders, specifically targeting type 2 diabetes and obesity by using brown fat stem cells. BRT has developed an ingredient derived from human adult stem cells, which can be used by third party companies in the development of their own skin care products. The ingredient was developed pursuant to BRT’s “brtx-C Cosmetic Program”. BRT’s Stem Pearls® brand offers plant stem cell-based cosmetic skincare products that are available for purchase online at www.stempearls.com.
	The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) for interim financial information. Accordingly, they do not include all of the information and disclosures required by GAAP for annual financial statements. In the opinion of management, such statements include all adjustments (consisting only of normal recurring items) which are considered necessary for a fair presentation of the condensed consolidated financial statements of the Company as of June 30, 2014 and for the three and six months ended June 30, 2014 and 2013. The results of operations for the three and six months ended June 30, 2014 are not necessarily indicative of the operating results for the full year ending December 31, 2014 or any other period. These unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and related disclosures of the Company as of December 31, 2013 and for the year then ended, which were filed with the Securities and Exchange Commission on Form 10-K on April 11, 2014.

Going_Concern_and_Management_P

Going Concern and Management Plans	6 Months Ended
	Jun. 30, 2014
Development Stage Enterprises [Abstract]	'
Going Concern and Management Plans	'
	Note 2 – Going Concern and Management Plans
	As of June 30, 2014, the Company had a working capital deficiency and a stockholders’ deficiency of $8,163,102 and $7,148,786, respectively. During the three and six months ended June 30, 2014, the Company incurred net losses of $1,333,139 and $3,002,815, respectively. These conditions raise substantial doubt about the Company’s ability to continue as a going concern.
	The Company's primary source of operating funds since inception has been equity and debt financings. The Company intends to continue to raise additional capital through debt and equity financings. There is no assurance that these funds will be sufficient to enable the Company to fully complete its development activities or attain profitable operations. If the Company is unable to obtain such additional financing on a timely basis and, notwithstanding any request the Company may make, the Company’s debt holders do not agree to convert their notes into equity or extend the maturity dates of their notes, the Company may have to curtail its development, marketing and promotional activities, which would have a material adverse effect on the Company’s business, financial condition and results of operations, and ultimately the Company could be forced to discontinue its operations and liquidate.
	The accompanying unaudited condensed consolidated financial statements have been prepared in conformity with GAAP, which contemplate continuation of the Company as a going concern and the realization of assets and satisfaction of liabilities in the normal course of business. The carrying amounts of assets and liabilities presented in the financial statements do not necessarily purport to represent realizable or settlement values. The unaudited condensed consolidated financial statements do not include any adjustment that might result from the outcome of this uncertainty.
	Subsequent to June 30, 2014, the Company has raised an aggregate of $205,000 through equity financing, has received research and development payments of $89,063, has extended the due date for the repayment of $4,000,000 of debt, and $76,669 and $2,992 of debt and accrued interest, respectively, has been converted into common stock. As a result, the Company expects to be able to fund its operations through October 2014. While there can be no assurance that it will be successful, the Company is in active negotiations to raise additional capital. As of the filing date of this report, the Company has notes payable with an aggregate principal balance of $244,063 which are either past due or payable on demand. The Company is currently in the process of negotiating extensions or discussing conversions to equity with respect to these notes. However, there can be no assurance that the Company will be successful in extending or converting these notes. See Note 8 – Subsequent Events for additional details.

Summary_of_Significant_Account

Summary of Significant Accounting Policies	6 Months Ended
	Jun. 30, 2014
Accounting Policies [Abstract]	'
Summary of Significant Accounting Policies	'
	Note 3 – Summary of Significant Accounting Policies
	Principles of Consolidation
	The unaudited condensed consolidated financial statements of the Company include the accounts of Stem Cell Cayman Ltd. (“Cayman”) and Stem Pearls, LLC. All significant intercompany transactions have been eliminated in the consolidation.
	Use of Estimates
	The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent liabilities at dates of the financial statements and the reported amounts of revenue and expenses during the periods. The Company’s significant estimates and assumptions include the recoverability and useful lives of long-lived assets, the fair value of the Company’s stock, stock-based compensation, warrants issued in connection with notes payable and the valuation allowance related to the Company’s deferred tax assets. Certain of the Company’s estimates, including the carrying amount of the intangible assets, could be affected by external conditions, including those unique to the Company and general economic conditions. It is reasonably possible that these external factors could have an effect on the Company’s estimates and could cause actual results to differ from those estimates.
	Concentrations and Credit Risk
	As of June, 30 2014, approximately 75% of the face value of the Company’s outstanding notes payable were received from a single entity (the “Bermuda Lender”). See Note 5 – Notes Payable for additional discussion of the Bermuda Lender.
	Revenue Recognition
	Research and Development Agreements
	The Company’s policy is to recognize research and development revenues on a straight-line basis over the term of the agreement, regardless of the payment structure, subject to potential acceleration upon achievement of contractually specified deliverables.
	On March 19, 2014, the Company entered into a one-year agreement with a Japanese pharmaceutical company to perform specified research and development activities related to stem cells. The agreement may be terminated earlier or extended, as provided for in the agreement. Payment terms are (1) $150,000 at commencement; (2) $50,000 upon achievement of a specified deliverable; and (3) $50,000 upon achievement of the final specified deliverable. As of June 30, 2014, the initial $150,000 payment had been received and $79,281 was recorded as deferred revenues on the condensed consolidated balance sheet.
	On March 24, 2014, the Company entered into a two-year agreement with a U.S. pharmaceutical company to perform specified research and development activities related to brown fat. The agreement may be terminated earlier or extended, as provided for in the agreement. Payment terms are (1) $250,000 at commencement; (2) $356,250 payable in four equal quarterly installments, subject to acceleration upon achieving a specified deliverable; and (3) $168,750 payable in two equal bi-annual installments, subject to acceleration upon achieving a specified deliverable. As of June 30, 2014, the initial $250,000 payment had been received and $145,694 was recorded as deferred revenues on the condensed consolidated balance sheet.
	During the three and six months ended June 30, 2014, the Company recognized revenue related to research and development agreements of $175,025. The Company did not recognize any revenue related to research and development agreements during the three and six months ended June 30, 2013.
	Other
	The Company’s policy is to recognize product sales when the risk of loss and title to the product transfers to the customer, after taking into account potential returns. The Company recognizes sublicensing and royalty revenue when all of the following have occurred: (i) persuasive evidence of an arrangement exists, (ii) the service is completed without further obligation, (iii) the sales price to the customer is fixed or determinable, and (iv) collectability is reasonably assured.
	During the three and six months ended June 30, 2014, the Company recognized revenue related to sales of Stem Pearls® skincare products of $916 and $1,291, respectively. During the three and six months ended June 30, 2013, the Company recognized  revenue related to sales of Stem Pearls® skincare products of $425 and $1,555, respectively.
	Net Loss Per Common Share
	Basic loss per common share is computed by dividing net loss by the weighted average number of vested common shares outstanding during the period. Diluted loss per common share is computed by dividing net loss by the weighted average number of vested common shares outstanding, plus the impact of common shares, if dilutive, resulting from the exercise of outstanding stock options and warrants, plus the conversion of convertible notes.
	The following securities are excluded from the calculation of weighted average dilutive common shares because their inclusion would have been anti-dilutive:
		June 30,
		2014	2013
	Options	8,709,000	3,963,000
	Warrants	6,325,751	4,370,890
	Convertible notes	1,482,093	-
	Total potentially dilutive shares	16,516,844	8,333,890
	Stock-Based Compensation
	The Company measures the cost of services received in exchange for an award of equity instruments based on the fair value of the award. For employees, the fair value of the award is measured on the grant date and for non-employees, the fair value of the award is generally re-measured on vesting dates and interim financial reporting dates until the service period is complete. The fair value amount is then recognized over the period during which services are required to be provided in exchange for the award, usually the vesting period. Since the shares underlying the Company’s 2010 Equity Participation Plan (the “Plan”) were registered on May 27, 2014, the Company estimates the fair value of the awards granted under the Plan based on the market value of its freely tradable common stock as reported by the OTC Bulletin Board. The fair value of the Company’s restricted equity instruments was estimated by management based on observations of the cash sales prices of both restricted shares and freely tradable shares. Awards granted to directors are treated on the same basis as awards granted to employees.
	Convertible Instruments
	GAAP requires companies to bifurcate conversion options from their host instruments and account for them as free standing derivative financial instruments according to certain criteria. The criteria include circumstances in which (a) the economic characteristics and risks of the embedded derivative instrument are not clearly and closely related to the economic characteristics and risks of the host contract, (b) the hybrid instrument that embodies both the embedded derivative instrument and the host contract is not re-measured at fair value under otherwise applicable generally accepted accounting principles with changes in fair value reported in earnings as they occur and (c) a separate instrument with the same terms as the embedded derivative instrument would be considered a derivative instrument. An exception to this rule is when the host instrument is deemed to be conventional, as that term is described under applicable GAAP.
	When the Company has determined that the embedded conversion options should not be bifurcated from their host instruments, the Company records, when necessary, discounts to convertible notes for the intrinsic value of conversion options embedded in debt instruments (the beneficial conversion feature) based upon the differences between the fair value of the underlying common stock at the commitment date of the note transaction and the effective conversion price embedded in the note. Debt discounts under these arrangements are amortized over the term of the related debt to their stated date of redemption.
	Subsequent Events
	The Company evaluates events that have occurred after the balance sheet date but before the financial statements are issued. Based upon the evaluation, the Company did not identify any recognized or non-recognized subsequent events that would have required adjustment or disclosure in the condensed consolidated financial statements, except as disclosed in Note 8.
	Recently Issued Accounting Pronouncements
	In May 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2014-09, “Revenue from Contracts with Customers,” (“ASU 2014-09”). ASU 2014-09 supersedes the revenue recognition requirements in Accounting Standards Codification (“ASC”) 605 - Revenue Recognition and most industry-specific guidance throughout the ASC. The standard requires that an entity recognizes revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the company expects to be entitled in exchange for those goods or services. ASU 2014-09 is effective on January 1, 2017 and should be applied retrospectively to each prior reporting period presented or retrospectively with the cumulative effect of initially applying ASU 2014-09 recognized at the date of initial application. The Company is currently evaluating the impact of the adoption of ASU 2014-09 on its condensed consolidated financial position and results of operations.
	In June 2014, the FASB issued ASU No. 2014-10,  “Development Stage Entities (Topic 915): Elimination of Certain Financial Reporting Requirements, Including an Amendment to Variable Interest Entities Guidance in Topic 810, Consolidation,” (“ASU 2014-10”). ASU 2014-10 removes  the definition of a development stage entity from the ASC, thereby removing the financial reporting distinction between development stage entities and other reporting entities from GAAP. In addition, ASU 2014-10 eliminates the requirements for development stage entities to (1) present inception-to-date information in the statements of operations, cash flows, and stockholders’ equity, (2) label the financial statements as those of a development stage entity, (3) disclose a description of the development stage activities in which the entity is engaged, and (4) disclose in the first year in which the entity is no longer a development stage entity that in prior years it had been in the development stage. ASU 2014-10  is effective for annual reporting periods beginning after December 15, 2014, and interim periods therein. Early adoption is permitted. The Company has elected to adopt  ASU 2014-10 effective with this Quarterly Report on Form 10-Q and its adoption resulted in the removal of previously required development stage disclosures. The Company’s planned principal operations are to develop technology using cell and tissue regenerative therapy protocols, primarily involving adult stem cells, allowing patients to undergo cellular-based treatments. The Company is currently seeking to establish a new laboratory facility and increase its capabilities for the further development of possible cellular-based treatment protocols, stem cell-related intellectual property and research applications. The Company’s activities are subject to significant risks and uncertainties, which are detailed in Note 2 – Going Concern and Management’s Plans.
	In June 2014, the FASB issued ASU No. 2014-12, "Compensation - Stock Compensation (Topic 718): Accounting for Share-Based Payments When the Terms of an Award Provide that a Performance Target Could be Achieved after the Requisite Service Period," ("ASU 2014-12"). The amendments in ASU 2014-12 require that a performance target that affects vesting and that could be achieved after the requisite service period be treated as a performance condition. A reporting entity should apply existing guidance in ASC  Topic No. 718, "Compensation - Stock Compensation" as it relates to awards with performance conditions that affect vesting to account for such awards. The amendments in ASU 2014-12 are effective for annual periods and interim periods within those annual periods beginning after December 15, 2015. Early adoption is permitted. Entities may apply the amendments in ASU 2014-12 either: (a) prospectively to all awards granted or modified after the effective date; or (b) retrospectively to all awards with performance targets that are outstanding as of the beginning of the earliest annual period presented in the financial statements and to all new or modified awards thereafter. The Company does not anticipate that the adoption of ASU 2014-12 will have a material impact on its condensed consolidated financial statements.

Accrued_Expenses_and_Other_Cur

Accrued Expenses and Other Current Liabilities	6 Months Ended
	Jun. 30, 2014
Accrued Liabilities and Other Liabilities [Abstract]	'
Accrued Expenses and Other Current Liabilities	'
	Note 4 – Accrued Expenses and Other Current Liabilities
	Accrued expenses and other current liabilities are comprised of the following:
		June 30,		December 31,
		2014		2013
		(unaudited)
	Credit card payable	$	4,772	$	6,000
	Accrued payroll and payroll taxes		757,205		672,535
	Other accrued expenses		393,989		495,817
	Deferred rent		-		2,310
	Total	$	1,155,966	$	1,176,662
	During the six months ended June 30, 2014, the Company received an aggregate of $15,015 in non-interest bearing advances from an officer of the Company and made aggregate repayments to a director and a family member of an officer of $40,005 of advances (plus accrued interest), such that the Company had no remaining liability at June 30, 2014. During the six months ended June 30, 2013, the Company received an aggregate of $75,385 in non-interest bearing advances from a director and an officer of the Company and made aggregate repayments of $69,370 of advances, such that the Company had a liability to the officer of $6,015 at June 30, 2013, which was due on demand.

Notes_Payable

Notes Payable	6 Months Ended
	Jun. 30, 2014
Notes Payable [Abstract]	'
Notes Payable	'
	Note 5 – Notes Payable
	A summary of the notes payable activity during the six months ended June 30, 2014 is presented below:
			Bermuda		Convertible			Other			Debt
			Lender		Notes			Notes			Discount			Total
	Outstanding, December 31, 2013		$	4,000,000	$	281,000		$	1,473,500		$	-240,491		$	5,514,009
	Issuances			500,000		175,000	[1]		-			-			675,000
	Exchanges for equity			-		-71,000			-203,000			-			-274,000
	Conversions to equity			-		-157,081			-			-			-157,081
	Repayments			-		-			-53,000			-			-53,000
	Setup of debt discount			-		-			-			-61,384			-61,384
	Amortization of debt discount			-		-			-			244,435			244,435
	Accretion of interest expense			-		11,250	[2]		73,058	[3]		9,934	[1]		94,242
	Outstanding, June 30, 2014		$	4,500,000	$	239,169	[4]	$	1,290,558		$	-47,506		$	5,982,221
		[1]	On March 10, 2014, a note with a principal amount of $30,000 was issued for cash consideration of $25,000 and bears no interest. The $5,000 difference was recorded as debt discount and will be accreted as interest expense over the term of the note. During the six months ended June 30, 2014, the Company accreted interest expense of $9,934 related to notes issued for cash consideration less than the principal amounts.
		[2]	During the six months ended June 30, 2014, pursuant to the terms of certain notes payable with maturity dates ranging from January 8, 2014 to March 18, 2014, the principal balances of the notes were increased from an aggregate of $60,000 to $71,250. The aggregate $11,250 of principal increases was accreted as interest expense.
		[3]	On April 1, 2014, in connection with the extension of certain notes payable with maturity dates ranging from August 8, 2013 to December 6, 2013 to new maturity dates ranging from October 1, 2014 to April 1, 2015, an aggregate of  $73,058 of accrued interest was added to the principal balance of the notes, increasing the aggregate principal balance from $652,500 to $725,558.
		[4]	As of June 30, 2014, a Convertible Note with a principal balance of $26,669 was convertible at the election of the holder.
	On May 8, 2014, Cayman issued the Bermuda Lender a one-year note payable in the principal amount of $500,000 which bears interest at 15% per annum payable at maturity. The note also provides for the mandatory prepayment of the principal amount to the extent of any monies received by the Company pursuant to the research and development agreements discussed in Note 3 – Summary of Significant Accounting Policies – Revenue Recognition – Research and Development Agreements. Interest on the entire principal amount of the note is payable until such time as the principal amount is paid in full. See Note 8 – Subsequent Events for details regarding maturity extensions and monies received pursuant to the research and development agreements. As of the filing date of this report, 76% of the face value of the Company’s outstanding notes payable were received from the Bermuda Lender and the maturity dates associated with these notes range from December 31, 2014 to May 7, 2015.
	Between January 17, 2014 and May 2, 2014, the Company issued Convertible Notes with an aggregate principal amount of $175,000, in consideration of $170,000 of new proceeds (a Convertible Note with a principal amount of $30,000 bears no interest and was issued for cash consideration of $25,000 and the $5,000 difference was recorded as debt discount and was accreted as interest over the term of the note resulting in a weighted average effective interest rate of 79%). Convertible Notes with an aggregate principal amount of $145,000 bear interest at a rate of 12% per annum payable upon maturity. The Convertible Notes were initially payable 3-12 months from the date of issuance. Of the $175,000 of Convertible Notes, $145,000 is convertible into shares of the Company’s common stock at the election of the Company during the period beginning five days prior to maturity and ending on the day immediately prior to maturity at the greater of (a) 55%-60%, depending on the particular note, of the fair value of the Company’s stock or (b) $0.05 per share. The remaining $30,000 is convertible into shares of the Company’s common stock at the election of the holder any time after September 10, 2014 at the lesser of (a) $0.50 per share or (b) 65% of the fair value of the Company’s common stock, but with a floor of $0.05 per share.
	During the six months ended June 30, 2014, the Company and certain lenders agreed to exchange notes payable with an aggregate principal balance of $274,000 and aggregate accrued interest of $19,932 for an aggregate of 1,101,453 shares of common stock and an immediately vested, two-year warrant to purchase 100,000 shares of common stock at an exercise price of $0.75 per share. The stock and warrants had an aggregate issuance date value of $330,436 and $12,590, respectively, and, as a result, the Company recorded a loss on extinguishment of $49,094. The lenders received piggyback registration rights related to the stock and the stock issuable pursuant to the warrants. See Note 8 – Subsequent Events for details regarding additional note exchanges.
	During the six months ended June 30, 2014, the Company elected to convert certain convertible notes payable with an aggregate principal balance of $100,000 and aggregate accrued interest of $6,187 into an aggregate of 442,778 shares of common stock at conversion prices ranging from $0.20 to $0.28 per share.
	During the six months ended June 30, 2014, the holders of certain convertible notes elected to convert notes with an aggregate principal balance of $57,081 and aggregate accrued interest of $3,500 for an aggregate of 282,685 shares of common stock at conversion prices ranging from $0.20 to $0.22 per share.
	During the six months ended June 30, 2014, the Company repaid certain notes payable with an aggregate principal balance of $53,000 and accrued interest of $11,219.
	During the six months ended June 30, 2014, the maturity dates of certain notes payable with an aggregate principal balance of $752,500 and interest rates ranging from 8% to 15% per annum were extended from maturity dates ranging from August 8, 2013 to December 31, 2013 to new maturity dates ranging from March 1, 2014 to April 1, 2015. In connection with the extensions, (a) the amount of interest due at maturity for a certain note was increased to $35,000 from $20,000, (b) an aggregate $73,058 of accrued interest was converted into the principal balance of the certain notes, (c) immediately vested, five-year warrants to purchase an aggregate of 100,000 shares of common stock at an exercise price of $0.75 per share were issued to the lenders, (d) previously outstanding warrants to purchase an aggregate of 90,000 shares of common stock had their exercise prices reduced to $0.75 per share from exercise prices ranging from $1.75 to $2.50 per share and (e) in the event a certain note is not paid in full on or before maturity, the Company agreed to  issue to the lender a five-year warrant to purchase 50,000 shares of common stock at an exercise price equal to 175% of the then fair market value of the Company’s common stock. As of the filing date of this report, one of the extended notes was past due.
	During the six months ended June 30, 2014, the contingently adjustable conversion ratios associated with certain notes payable were resolved. The Company estimated the intrinsic value of the embedded conversion options based upon the differences between the fair value of the underlying common stock at the commitment date of the note transaction and the effective conversion price embedded in the note. The Company recognized the $41,384 intrinsic value related to these beneficial conversion features as debt discount and the entire amount was amortized during the three and six months ended June 30, 2014.

Commitments_and_Contingencies

Commitments and Contingencies	6 Months Ended
	Jun. 30, 2014
Commitments and Contingencies Disclosure [Abstract]	'
Commitments and Contingencies	'
	Note 6 – Commitments and Contingencies
	Operating Lease
	On February 4, 2014, the Company and the landlord agreed to the surrender of a portion of the Jupiter, Florida leased premises and also extended the term of the lease to July 31, 2014. The amended lease provides for a base rent of $962 per month. On July 29, 2014, the Company and the landlord further amended the lease agreement such that, commencing on July 31, 2014, the lease shall automatically renew for successive three calendar month periods; provided, however, that both parties shall have the right to terminate the lease effective at the end of any such renewal term by providing written notice to the other party at least 30 days prior to the expiration of the applicable renewal term.
	On February 11, 2014, the Company executed a Facility Use Agreement with a stem cell treatment company (“SCTC”) which permits the Company to utilize the SCTC’s laboratory facility and one office for research associated with its culturing and medical device license. Payment terms are $3,750 through March 31, 2014 and $100 per day for usage beyond that date.
	Rent expense amounted to approximately $4,000 and $14,000 during the three and six months ended June 30, 2014, respectively, and $16,000 and $52,000 during the three and six months ended June 30, 2013, respectively. Rent expense is reflected in general and administrative expenses in the condensed consolidated statements of operations.
	Consulting Agreements
	On February 20, 2014, the Company executed a two-year consulting agreement with the Physiatrist-In-Chief Emeritus for the Hospital for Special Surgery in New York City to become the Company’s Chief Medical Advisor for Spine Medicine pursuant to which he oversees the clinical aspects of the brtxDISC™ Program. The agreement may be terminated earlier or extended, as provided for in the agreement. Pursuant to the agreement, the consultant is entitled to receive  $10,000 per month, escalating to $20,000 per month upon the FDA approval of the Company’s Investigational New Drug or Investigational Device Exemption application with respect to its brtxDISC™ Program. In addition, the Company granted the consultant a five-year option to purchase 300,000 shares of common stock at an exercise price of $0.65 per share, pursuant to the Plan. The option vests ratably over three years on the grant date anniversaries and the grant date value of $67,830 will be recognized proportionate to the vesting period.
	On March 12, 2014, as additional compensation for consulting services, the Company granted to a consultant an immediately vested, five-year warrant to purchase 100,000 shares of common stock at an exercise price of $0.53 per share. In addition, warrants to purchase an aggregate of 280,000 shares of common stock had their exercise prices reduced to $0.53 per share from $1.50 per share and such warrants, as well as a warrant to purchase 20,000 shares of common stock, had their term extended to March 12, 2019. The grant date value of the issued warrant of $23,360 along with the incremental value related to the modification of the outstanding warrants of $30,366 was recognized during the six months ended June 30, 2014 as stock-based compensation expense, which is reflected as consulting expense in the condensed consolidated statements of operations.
	On March 14, 2014, the Company executed an agreement, which will continue until terminated by either party, appointing a new Scientific Advisory Board member. Pursuant to the agreement, the Company immediately granted the new Advisor a five-year option to purchase 25,000 shares of common stock at an exercise price of $0.50 per share, pursuant to the Plan. The option vests as follows: (i) 12,500 shares immediately and (ii) 12,500 shares on the first anniversary of the grant date. In addition, on each annual anniversary date of the agreement, the Advisor is entitled to a new five-year option to purchase 5,000 shares of the Company’s common stock at an exercise price equal to the then fair market value of the common stock. The option grant date value of $5,860 will be recognized proportionate to the vesting period.
	On June 27, 2014, a February 17, 2011 agreement for marketing consulting services that had expired on December 31, 2013 was further amended. Pursuant to the amendment, the agreement was reinstated effective as of April 1, 2014 and will continue in effect until December 31, 2014 (the “New Term”). In consideration of services rendered during the New Term and the cancellation of the Company’s obligation to pay $65,000 to the consultant, the Company issued to a designee of the consultant 500,000 shares of common stock and issued to the consultant an immediately vested five-year warrant to purchase 250,000 shares of common stock at an exercise price of $1.00 per share. The common stock and warrant had grant date values of $110,000 and $37,500, respectively, which were recognized immediately.
	On June 27, 2014, a February 17, 2011 agreement for business advisory services that had expired on December 31, 2013 was further amended. Pursuant to the amendment, the agreement was reinstated effective as of April 1, 2014 and will continue in effect until December 31, 2014 (the “New Term”). In consideration of services rendered during the New Term, the Company agreed to pay a cash fee of $16,667 per month and the Company granted an immediately vested five-year warrant to purchase 250,000 shares of common stock at an exercise price of $1.00 per share. The warrant had a grant date value of $37,500 which was recognized immediately.
	On June 27, 2014, an August 16, 2012 agreement for scientific advisory services was further extended to August 16, 2016 such that the consultant will continue to serve as Chairman of the Company’s Scientific Advisory Board, will earn $10,000 per month and will be entitled to specified expense reimbursements. In addition, the Company granted a ten-year option to purchase 300,000 shares of common stock at an exercise price of $0.285 per share, pursuant to the Plan. The option vests as follows: (i) 150,000 shares on August 16, 2015 and (ii) 150,000 shares on August 16, 2016. The option grant date value of $81,000 will be recognized proportionate to the vesting period.
	During the six months ended June 30, 2014, the Company issued an aggregate of 378,458 additional shares of common stock valued at $130,398 to consultants pursuant to consulting agreements.
	See Note 8 – Subsequent Events for details regarding an additional consulting agreement.
	Research Agreement
	On May 9, 2014, the Company entered into an amendment to its Research Agreement, dated June 15, 2012, with the University of Utah (the “University”) (the “Utah Agreement”). Pursuant to the amendment, the parties agreed that (i) no fees are payable by the Company to the University pursuant to the Utah Agreement for the first five monthly payments in 2014 ($208,335 of fees in total were cancelled, of which, $104,168 was accrued for as of March 31, 2014),  (ii) effective with the payment due on June 15, 2014, the monthly fee payable by the Company to the University pursuant to the Utah Agreement will be reduced from $41,667 to $20,000 and (iii) the scope of the work to be performed by the University pursuant to the Utah Agreement will be reduced. The Utah Agreement is scheduled to expire on June 14, 2015. Concurrently with the execution of the amendment, the Company paid $323,336 to the University, representing the balance of all fees payable by the Company to date pursuant to the Utah Agreement. As a result, the Company recorded a gain on settlement in the amount of $166,668 during the three and six months ended June 30, 2014.
	Board of Directors
	On June 27, 2014, a director of the Company resigned due to other business commitments. In consideration of director services performed to date, the Company agreed to pay an aggregate of $80,000 (of which, $50,000 was previously earned and accrued for), payable as follows: (i) $30,000 immediately and (ii) the $50,000 balance in six equal monthly installments commencing on July 31, 2014. In addition, all outstanding options held by the director which were not exercisable as of the date of resignation shall become exercisable on the earlier of (i) the date on which such options are scheduled to become exercisable or (ii) December 31, 2014, and all outstanding options shall remain exercisable until their respective expiration dates notwithstanding the director’s resignation. As a result of the modification of the options, the Company recorded incremental stock-based compensation expense of $96,250.
	On June 27, 2014, the Company elected two new directors. Concurrently with the election, the Company granted the directors ten-year options to purchase an aggregate of 600,000 shares of common stock at an exercise price of $0.285 per share, pursuant to the Plan. The options vest as follows: (i) an aggregate of 200,000 shares on the date of grant; (ii) an aggregate of 200,000 shares on the first anniversary of the date of grant; and (iii) an aggregate of 200,000 shares on the second anniversary of the date of grant. The options have an aggregate grant date value of $144,000 which will be recognized proportionate to the vesting period.
	Claims
	In November 2013, an action was commenced in the Circuit Court of Palm Beach County, Florida by an alleged former consultant against the Company. The action is associated with an alleged loan made in 2009 and an alleged consulting/employment agreement entered into with the Company effective in 2009. Pursuant to the action, the plaintiff is seeking to recover an unspecified amount of damages but at least approximately $193,000 of cash and warrants for the purchase of 80,000 shares of the Company’s common stock. During March 2014, the Company filed its answer to the complaint wherein it denied the allegations and entered thirteen affirmative defenses. Procedural hearings commenced in July 2014. The Company has not accrued for a loss associated with this matter as it believes that the claims are without merit and it intends to vigorously defend this matter.
	The Company records legal costs associated with loss contingencies as incurred and accrues for all probable and estimable settlements.

Stockholders_Deficiency

Stockholders' Deficiency	6 Months Ended
	Jun. 30, 2014
Stockholders' Equity Note [Abstract]	'
Stockholders' Deficiency	'
	Note 7 – Stockholders’ Deficiency
	2010 Equity Participation Plan
	On February 18, 2014, the Board of Directors of the Company approved an increase in the number of shares of common stock authorized to be issued pursuant to the Plan from 6,000,000 to 12,000,000.
	Common Stock and Warrant Offerings
	During the six months ended June 30, 2014, the Company issued an aggregate of 2,968,651 shares of common stock at prices ranging from $0.25 to $0.45 per unit to investors for aggregate gross proceeds of $945,000. In connection with the purchases, the Company issued warrants to purchase an aggregate of 729,861 shares of common stock with exercise prices ranging from $0.30 to $0.75 per share. The warrants have terms ranging from two to five years.
	See Note 5 – Notes Payable for details associated with common stock issued in conjunction with the conversion and exchange of notes payable. See Note 6 – Commitments and Contingencies – Consulting Agreements for details associated with common stock issued pursuant to consulting agreements. See Note 7 – Stockholders’ Deficiency – Warrant Exchange and Reload Program for details associated with common stock issued pursuant to warrant exercises. See Note 8 – Subsequent Events for details regarding additional issuances of common stock and warrants for cash.
	Warrant and Option Valuation
	The Company has computed the fair value of warrants and options granted using the Black-Scholes option pricing model. Option forfeitures are estimated at the time of valuation and reduce expense ratably over the vesting period. This estimate will be adjusted periodically based on the extent to which actual option forfeitures differ, or are expected to differ, from the previous estimate, when it is material. The Company estimated forfeitures related to option grants at annual rates ranging from 0% to 5% for options granted during the six months ended June 30, 2014. The expected term used for warrants and options issued to non-employees is the contractual life and the expected term used for options issued to employees is the estimated period of time that options granted are expected to be outstanding. The Company utilizes the “simplified” method to develop an estimate of the expected term of “plain vanilla” employee option grants. Since the Company’s stock has not been publicly traded for a sufficiently long period of time, the Company is utilizing an expected volatility figure based on a review of the historical volatilities, over a period of time, equivalent to the expected life of the instrument being valued, of similarly positioned public companies within its industry. The risk-free interest rate was determined from the implied yields from U.S. Treasury zero-coupon bonds with a remaining term consistent with the expected term of the instrument being valued.
	Warrant Exercise and Reload Program
	On November 27, 2013, the Company initiated a limited time program (the “Warrant Exercise and Reload Program”) which, at the election of any warrant holder, would permit them to immediately exercise their outstanding exercisable warrants at an exercise price of $0.30 per share. In connection with the exercise of the warrant, in addition to having received the number of shares pursuant to such exercise, each holder would receive a new warrant for the same number of shares purchased with an exercise price of $0.75 per share and an expiration date of December 31, 2015. The terms of the newly issued warrant permit the Company to redeem the new warrant for a total of $1.00 if the common stock of the Company trades above $1.25 for five consecutive trading days. Under the Warrant Exercise and Reload Program, warrants to purchase an aggregate of 266,667 shares of common stock were exercised during the six months ended June 30, 2014 for aggregate gross proceeds of $80,000. The Company recognized a warrant modification charge of $0 and $30,128 during the three and six months ended June 30, 2014, respectively, which represents the incremental value of the modified warrant and new warrant combined, as compared to the original warrant value, all valued as of the respective modification dates.
	Stock Warrants
	See Note 5 – Notes Payable for details associated with the issuance of warrants in connection with note issuances and the exchange of notes payable. See Note 6 – Commitments and Contingencies – Consulting Agreements for details associated with the issuance of warrants as compensation. See Note 7 – Stockholders’ Deficiency – Common Stock and Warrant Offerings for details associated with the issuance of warrants in connection with common stock and warrant offerings. See Note 8 – Subsequent Events for details associated with the issuance of warrants as compensation.
	In applying the Black-Scholes option pricing model to warrants granted, the Company used the following weighted average assumptions:
			For the Three Months Ended				For the Six Months Ended
			June 30,				June 30,
			2014		2013		2014		2013
	Risk free interest rate		1.64	%	0.93	%	1.58	%	0.81	%
	Expected term (years)		5		5		4.78		4.98
	Expected volatility		120	%	135	%	120	%	135	%
	Expected dividends		0	%	0	%	0	%	0	%
	The weighted average estimated fair value of the warrants granted during the three and six months ended June 30, 2014 was $0.16 and $0.19 per share, respectively. The weighted average estimated fair value of the warrants granted during the three and six months ended June 30, 2013 was $0.36 and $0.63 per share, respectively.
	The Company recorded stock–based compensation expense of $113,400 and $167,126 during the three and six months ended June 30, 2014, respectively, and a credit of $3,596 and expense of $20,604 during the three and six months ended June 30, 2013, respectively, related to stock warrants issued as compensation, which is reflected as consulting expense in the condensed consolidated statements of operations. As of June 30, 2014, there was no unrecognized stock-based compensation expense related to stock warrants.
	A summary of the stock warrant activity during the six months ended June 30, 2014 is presented below:
									Weighted
					Weighted				Average
					Average				Remaining
			Number of		Exercise				Life		Intrinsic
			Warrants		Price				In Years		Value
	Outstanding, December 31, 2013		4,795,890		$	1.39
	Granted		1,796,528			0.74
	Exercised		-266,667			0.3	[1]
	Forfeited		-			-
	Outstanding, June 30, 2014		6,325,751		$	1.05			3.2		$	-
	Exercisable, June 30, 2014		5,625,751		$	0.99			3.2		$	-
	The following table presents information related to stock warrants at June 30, 2014:
	Warrants Outstanding							Warrants Exercisable
								Weighted
								Average			Exercisable
	Exercise				Number of			Remaining Life			Number of
	Price				Warrants			In Years			Warrants
	$	0.3			650,000			4.9			650,000
		0.5			40,000			0.1			40,000
		0.53			380,000			3.9			380,000
		0.75			2,632,557			2.3			2,632,557
		0.94			50,000			4.4			50,000
		1			550,000			4.9			550,000
		1.5			862,800			3			862,800
		1.75			70,000			3.6			70,000
		2			123,530			4.4			123,530
		2.5			60,000			3			60,000
		3			36,864			3.8			36,864
		4			170,000			3.6			170,000
		Variable	[2]		700,000			-			-
					6,325,751			3.2			5,625,751
		[1]	Warrants to purchase an aggregate of 266,667 shares of common stock had their exercise prices reduced to $0.30 per share pursuant to the Warrant Exercise and Reload Program. The warrants previously had exercise prices that ranged from $1.50 to $4.00 per share. See Note 7 – Stockholders’ Deficiency – Warrant Exercise and Reload Program.
		[2]	Warrants to purchase 700,000 shares of common stock have an exercise price which is the greater of $1.50 per share or the fair market value of the common stock on the date certain performance criteria are met. Exercisability of warrants is subject to satisfaction of certain performance criteria which did not occur during the six months ended June 30, 2014.
	Stock Options
	See Note 6 – Commitments and Contingencies for details associated with the issuance and modification of options to consultants and directors.
	In applying the Black-Scholes option pricing model to stock options granted, the Company used the following weighted average assumptions:
			For the Three Months Ended						For the Six Months Ended
			June 30,						June 30,
			2014			2013			2014			2013
	Risk free interest rate		1.93	%		1.13	%		1.61	%		1.81	%
Expected term (years)		6.88			5			5.81			9.62
Expected volatility		120	%		135	%		120	%		135	%
Expected dividends		0	%		0	%		0	%		0	%
The weighted average estimated fair value of the options granted during the three and six months ended June 30, 2014 was $0.25 and $0.24 per share, respectively. The weighted average estimated fair value of the options granted during the three and six months ended June 30, 2013 was $0.41 and $0.74 per share, respectively.
Between February 18, 2014 and March 12, 2014, the Company granted ten-year options to employees and directors to purchase an aggregate of 2,415,000 shares of common stock at exercise prices ranging from $0.53 to $0.65 per share, pursuant to the Plan. The shares vest as follows: (i) 831,669 shares immediately and (ii) 1,589,331 shares ratably over two years on the grant date anniversaries. The aggregate grant date value of $566,483 will be recognized proportionate to the vesting period.
On June 16, 2014, the Company granted a five-year option to a consultant to purchase 60,000 shares of common stock at an exercise price of $0.39 per share, pursuant to the Plan. The shares vest ratably over three months on the grant date anniversaries. The grant date value of $18,600 will be recognized proportionate to the vesting period.
The following table presents information related to stock option expense:
																Weighted
																Average
		For The Three Months Ended						For The Six Months Ended					Unrecognized			Amortization
		June 30,						June 30,					at June 30,			Period
		2014			2013			2014			2013		2014			(Years)
Consulting		$	150,962		$	19,125		$	251,575		$	64,250	$	166,128	[1]		1.8
Research and development			32,324			40,127			153,714			123,859		193,573	[2]		1.8
General and administrative			21,280			52,681			104,979			106,431		151,659			1.6
		$	204,566		$	111,933		$	510,268		$	294,540	$	511,360			1.8
	[1]	Includes $8,363 of unrecognized expense that is subject to non-employee mark-to-market adjustments.
	[2]	Includes $152,710 of unrecognized expense that is subject to non-employee mark-to-market adjustments.
A summary of the stock option activity during the six months ended June 30, 2014 is presented below:
								Weighted
					Weighted			Average
					Average			Remaining
		Number of			Exercise			Life			Intrinsic
		Options			Price			In Years			Value
Outstanding, December 31, 2013			5,043,000		$	1.03
Granted			3,700,000			0.55
Exercised			-			-
Forfeited			-34,000			1.31
Outstanding, June 30, 2014			8,709,000		$	0.83			8.4		$	13,500
Exercisable, June 30, 2014			5,323,167		$	0.97			7.4		$	3,000
The following table presents information related to stock options at June 30, 2014:
Options Outstanding						Options Exercisable
						Weighted
			Outstanding			Average			Exercisable
	Exercise		Number of			Remaining Life			Number of
	Price		Options			In Years			Options
$	0.285			900,000			10			200,000
	0.39			60,000			-			-
	0.5			345,000			5.4			332,500
	0.53			40,000			9.7			40,000
	0.6			980,000			9.3			490,000
	0.65			2,675,000			5.6			791,667
	1			131,000			8.1			81,000
	1.05			2,270,000			7.6			2,270,000
	1.1			5,000			2.9			5,000
	1.2			10,000			1.9			10,000
	1.25			43,000			2.4			43,000
	1.4			350,000			5.4			160,000
	1.5			900,000			8.4			900,000
				8,709,000			7.4			5,323,167
Common Stock Awards
See Note 8 – Subsequent Events for details associated with the issuance of common stock as consultant compensation.
The following table presents information related to common stock award expense:
		For The Three Months Ended						For The Six Months Ended					Unrecognized
		June 30,						June 30,					at June 30,
		2014			2013			2014			2013		2014
Consulting		$	224,500		$	6,001		$	234,500		$	54,001	$	-
Research and development			1,827			-			5,898			723		-
General and administrative			-			-			-			-		-
		$	226,327		$	6,001		$	240,398		$	54,724	$	-
A summary of common stock award activity for the six months ended June 30, 2014 is presented below:
					Weighted
					Average			Total
		Number of			Grant Date			Grant Date
		Shares			Fair Value			Fair Value
Non-vested, December 31, 2013			-		$	-		$	-
Granted			878,458			0.27			240,398
Vested			-878,458			-0.27			-240,398
Forfeited			-			-			-
Non-vested, June 30, 2014			-		$	-		$	-

Subsequent_Events

Subsequent Events	6 Months Ended
	Jun. 30, 2014
Subsequent Events [Abstract]	'
Subsequent Events	'
	Note 8 - Subsequent Events
	Consulting Agreement
	On July 23, 2014, the Company entered into a one-year agreement with a consultant to provide services related to the introduction to potential strategic partners and other alliance candidates with regard to research and development arrangements and other business transactions. In exchange for services provided by the consultant during the term, the Company agreed to issue 30,000 shares of common stock of the Company for each complete month during the term.
	Notes Payable
	On July 15, 2014, the Company received $89,063 pursuant to the research and development agreements discussed in Note 3 – Summary of Significant Accounting Policies – Revenue Recognition – Research and Development Agreements which triggered the mandatory principal prepayment of $89,063 of the note payable that was issued to the Bermuda Lender on May 8, 2014. As of the filing date of this report, the mandatory prepayment was unpaid.
	On or about August 13, 2014, Cayman and the Bermuda Lender agreed to extend the maturity date of certain notes issued by Cayman to the Bermuda Lender in the aggregate principal amount of $4,000,000 from July 31, 2014 to December 31, 2014. In consideration of the extension, the Company issued to the Bermuda Lender 550,000 shares of common stock.
	Subsequent to June 30, 2014, the Company and certain lenders agreed to exchange notes payable with an aggregate principal balance of $76,669 and aggregate accrued interest of $2,992 for an aggregate of 489,505 shares of common stock.
	Common Stock and Warrant Offerings
	Subsequent to June 30, 2014, the Company issued an aggregate of 703,333 shares of common stock at prices ranging from $0.25 to $0.30 per unit to investors for aggregate gross proceeds of $205,000. In connection with the purchases, the Company issued five-year warrants to purchase an aggregate of 175,833 shares of common stock at an exercise price of $0.75 per share.
	Stock-Based Compensation
	Subsequent to June 30, 2014, the Company issued an aggregate of 45,273 shares of common stock to consultants pursuant to consulting agreements.
	Subsequent to June 30, 2014, the Company issued to a consultant an immediately vested five-year warrant to purchase 10,000 shares of the Company’s common stock at an exercise price of $0.75 per share.

Summary_of_Significant_Account1

Summary of Significant Accounting Policies (Policies)	6 Months Ended
	Jun. 30, 2014
Accounting Policies [Abstract]	'
Principles of Consolidation	'
	Principles of Consolidation
	The unaudited condensed consolidated financial statements of the Company include the accounts of Stem Cell Cayman Ltd. (“Cayman”) and Stem Pearls, LLC. All significant intercompany transactions have been eliminated in the consolidation.
Use of Estimates	'
	Use of Estimates
	The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent liabilities at dates of the financial statements and the reported amounts of revenue and expenses during the periods. The Company’s significant estimates and assumptions include the recoverability and useful lives of long-lived assets, the fair value of the Company’s stock, stock-based compensation, warrants issued in connection with notes payable and the valuation allowance related to the Company’s deferred tax assets. Certain of the Company’s estimates, including the carrying amount of the intangible assets, could be affected by external conditions, including those unique to the Company and general economic conditions. It is reasonably possible that these external factors could have an effect on the Company’s estimates and could cause actual results to differ from those estimates.
Concentrations and Credit Risk	'
	Concentrations and Credit Risk
	As of June, 30 2014, approximately 75% of the face value of the Company’s outstanding notes payable were received from a single entity (the “Bermuda Lender”). See Note 5 – Notes Payable for additional discussion of the Bermuda Lender.
Revenue Recognition	'
	Revenue Recognition
	Research and Development Agreements
	The Company’s policy is to recognize research and development revenues on a straight-line basis over the term of the agreement, regardless of the payment structure, subject to potential acceleration upon achievement of contractually specified deliverables.
	On March 19, 2014, the Company entered into a one-year agreement with a Japanese pharmaceutical company to perform specified research and development activities related to stem cells. The agreement may be terminated earlier or extended, as provided for in the agreement. Payment terms are (1) $150,000 at commencement; (2) $50,000 upon achievement of a specified deliverable; and (3) $50,000 upon achievement of the final specified deliverable. As of June 30, 2014, the initial $150,000 payment had been received and $79,281 was recorded as deferred revenues on the condensed consolidated balance sheet.
	On March 24, 2014, the Company entered into a two-year agreement with a U.S. pharmaceutical company to perform specified research and development activities related to brown fat. The agreement may be terminated earlier or extended, as provided for in the agreement. Payment terms are (1) $250,000 at commencement; (2) $356,250 payable in four equal quarterly installments, subject to acceleration upon achieving a specified deliverable; and (3) $168,750 payable in two equal bi-annual installments, subject to acceleration upon achieving a specified deliverable. As of June 30, 2014, the initial $250,000 payment had been received and $145,694 was recorded as deferred revenues on the condensed consolidated balance sheet.
	During the three and six months ended June 30, 2014, the Company recognized revenue related to research and development agreements of $175,025. The Company did not recognize any revenue related to research and development agreements during the three and six months ended June 30, 2013.
	Other
	The Company’s policy is to recognize product sales when the risk of loss and title to the product transfers to the customer, after taking into account potential returns. The Company recognizes sublicensing and royalty revenue when all of the following have occurred: (i) persuasive evidence of an arrangement exists, (ii) the service is completed without further obligation, (iii) the sales price to the customer is fixed or determinable, and (iv) collectability is reasonably assured.
	During the three and six months ended June 30, 2014, the Company recognized revenue related to sales of Stem Pearls® skincare products of $916 and $1,291, respectively. During the three and six months ended June 30, 2013, the Company recognized  revenue related to sales of Stem Pearls® skincare products of $425 and $1,555, respectively.
Net Loss Per Common Share	'
	Net Loss Per Common Share
	Basic loss per common share is computed by dividing net loss by the weighted average number of vested common shares outstanding during the period. Diluted loss per common share is computed by dividing net loss by the weighted average number of vested common shares outstanding, plus the impact of common shares, if dilutive, resulting from the exercise of outstanding stock options and warrants, plus the conversion of convertible notes.
	The following securities are excluded from the calculation of weighted average dilutive common shares because their inclusion would have been anti-dilutive:
		June 30,
		2014	2013
	Options	8,709,000	3,963,000
	Warrants	6,325,751	4,370,890
	Convertible notes	1,482,093	-
	Total potentially dilutive shares	16,516,844	8,333,890
Stock-Based Compensation	'
	Stock-Based Compensation
	The Company measures the cost of services received in exchange for an award of equity instruments based on the fair value of the award. For employees, the fair value of the award is measured on the grant date and for non-employees, the fair value of the award is generally re-measured on vesting dates and interim financial reporting dates until the service period is complete. The fair value amount is then recognized over the period during which services are required to be provided in exchange for the award, usually the vesting period. Since the shares underlying the Company’s 2010 Equity Participation Plan (the “Plan”) were registered on May 27, 2014, the Company estimates the fair value of the awards granted under the Plan based on the market value of its freely tradable common stock as reported by the OTC Bulletin Board. The fair value of the Company’s restricted equity instruments was estimated by management based on observations of the cash sales prices of both restricted shares and freely tradable shares. Awards granted to directors are treated on the same basis as awards granted to employees.
Convertible Instruments	'
	Convertible Instruments
	GAAP requires companies to bifurcate conversion options from their host instruments and account for them as free standing derivative financial instruments according to certain criteria. The criteria include circumstances in which (a) the economic characteristics and risks of the embedded derivative instrument are not clearly and closely related to the economic characteristics and risks of the host contract, (b) the hybrid instrument that embodies both the embedded derivative instrument and the host contract is not re-measured at fair value under otherwise applicable generally accepted accounting principles with changes in fair value reported in earnings as they occur and (c) a separate instrument with the same terms as the embedded derivative instrument would be considered a derivative instrument. An exception to this rule is when the host instrument is deemed to be conventional, as that term is described under applicable GAAP.
	When the Company has determined that the embedded conversion options should not be bifurcated from their host instruments, the Company records, when necessary, discounts to convertible notes for the intrinsic value of conversion options embedded in debt instruments (the beneficial conversion feature) based upon the differences between the fair value of the underlying common stock at the commitment date of the note transaction and the effective conversion price embedded in the note. Debt discounts under these arrangements are amortized over the term of the related debt to their stated date of redemption.
Subsequent Events	'
	Subsequent Events
	The Company evaluates events that have occurred after the balance sheet date but before the financial statements are issued. Based upon the evaluation, the Company did not identify any recognized or non-recognized subsequent events that would have required adjustment or disclosure in the condensed consolidated financial statements, except as disclosed in Note 8.
Recently Issued Accounting Pronouncements	'
	Recently Issued Accounting Pronouncements
	In May 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2014-09, “Revenue from Contracts with Customers,” (“ASU 2014-09”). ASU 2014-09 supersedes the revenue recognition requirements in Accounting Standards Codification (“ASC”) 605 - Revenue Recognition and most industry-specific guidance throughout the ASC. The standard requires that an entity recognizes revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the company expects to be entitled in exchange for those goods or services. ASU 2014-09 is effective on January 1, 2017 and should be applied retrospectively to each prior reporting period presented or retrospectively with the cumulative effect of initially applying ASU 2014-09 recognized at the date of initial application. The Company is currently evaluating the impact of the adoption of ASU 2014-09 on its condensed consolidated financial position and results of operations.
	In June 2014, the FASB issued ASU No. 2014-10,  “Development Stage Entities (Topic 915): Elimination of Certain Financial Reporting Requirements, Including an Amendment to Variable Interest Entities Guidance in Topic 810, Consolidation,” (“ASU 2014-10”). ASU 2014-10 removes  the definition of a development stage entity from the ASC, thereby removing the financial reporting distinction between development stage entities and other reporting entities from GAAP. In addition, ASU 2014-10 eliminates the requirements for development stage entities to (1) present inception-to-date information in the statements of operations, cash flows, and stockholders’ equity, (2) label the financial statements as those of a development stage entity, (3) disclose a description of the development stage activities in which the entity is engaged, and (4) disclose in the first year in which the entity is no longer a development stage entity that in prior years it had been in the development stage. ASU 2014-10  is effective for annual reporting periods beginning after December 15, 2014, and interim periods therein. Early adoption is permitted. The Company has elected to adopt  ASU 2014-10 effective with this Quarterly Report on Form 10-Q and its adoption resulted in the removal of previously required development stage disclosures. The Company’s planned principal operations are to develop technology using cell and tissue regenerative therapy protocols, primarily involving adult stem cells, allowing patients to undergo cellular-based treatments. The Company is currently seeking to establish a new laboratory facility and increase its capabilities for the further development of possible cellular-based treatment protocols, stem cell-related intellectual property and research applications. The Company’s activities are subject to significant risks and uncertainties, which are detailed in Note 2 – Going Concern and Management’s Plans.
	In June 2014, the FASB issued ASU No. 2014-12, "Compensation - Stock Compensation (Topic 718): Accounting for Share-Based Payments When the Terms of an Award Provide that a Performance Target Could be Achieved after the Requisite Service Period," ("ASU 2014-12"). The amendments in ASU 2014-12 require that a performance target that affects vesting and that could be achieved after the requisite service period be treated as a performance condition. A reporting entity should apply existing guidance in ASC  Topic No. 718, "Compensation - Stock Compensation" as it relates to awards with performance conditions that affect vesting to account for such awards. The amendments in ASU 2014-12 are effective for annual periods and interim periods within those annual periods beginning after December 15, 2015. Early adoption is permitted. Entities may apply the amendments in ASU 2014-12 either: (a) prospectively to all awards granted or modified after the effective date; or (b) retrospectively to all awards with performance targets that are outstanding as of the beginning of the earliest annual period presented in the financial statements and to all new or modified awards thereafter. The Company does not anticipate that the adoption of ASU 2014-12 will have a material impact on its condensed consolidated financial statements.

Summary_of_Significant_Account2

Summary of Significant Accounting Policies (Tables)	6 Months Ended
	Jun. 30, 2014
Accounting Policies [Abstract]	'
Schedule of Weighted Average Number of Shares	'
	The following securities are excluded from the calculation of weighted average dilutive common shares because their inclusion would have been anti-dilutive:
		June 30,
		2014	2013
	Options	8,709,000	3,963,000
	Warrants	6,325,751	4,370,890
	Convertible notes	1,482,093	-
	Total potentially dilutive shares	16,516,844	8,333,890

Accrued_Expenses_and_Other_Cur1

Accrued Expenses and Other Current Liabilities (Tables)	6 Months Ended
	Jun. 30, 2014
Accrued Liabilities and Other Liabilities [Abstract]	'
Accrued Expenses and Other Current Liabilities	'
	Accrued expenses and other current liabilities are comprised of the following:
		June 30,		December 31,
		2014		2013
		(unaudited)
	Credit card payable	$	4,772	$	6,000
	Accrued payroll and payroll taxes		757,205		672,535
	Other accrued expenses		393,989		495,817
	Deferred rent		-		2,310
	Total	$	1,155,966	$	1,176,662

Notes_Payable_Tables

Notes Payable (Tables)	6 Months Ended
	Jun. 30, 2014
Disclosure Notes Payable Additional Information [Abstract]	'
Notes Payable	'
	A summary of the notes payable activity during the six months ended June 30, 2014 is presented below:
			Bermuda		Convertible			Other			Debt
			Lender		Notes			Notes			Discount			Total
	Outstanding, December 31, 2013		$	4,000,000	$	281,000		$	1,473,500		$	-240,491		$	5,514,009
	Issuances			500,000		175,000	[1]		-			-			675,000
	Exchanges for equity			-		-71,000			-203,000			-			-274,000
	Conversions to equity			-		-157,081			-			-			-157,081
	Repayments			-		-			-53,000			-			-53,000
	Setup of debt discount			-		-			-			-61,384			-61,384
	Amortization of debt discount			-		-			-			244,435			244,435
	Accretion of interest expense			-		11,250	[2]		73,058	[3]		9,934	[1]		94,242
	Outstanding, June 30, 2014		$	4,500,000	$	239,169	[4]	$	1,290,558		$	-47,506		$	5,982,221
		[1]	On March 10, 2014, a note with a principal amount of $30,000 was issued for cash consideration of $25,000 and bears no interest. The $5,000 difference was recorded as debt discount and will be accreted as interest expense over the term of the note. During the six months ended June 30, 2014, the Company accreted interest expense of $9,934 related to notes issued for cash consideration less than the principal amounts.
		[2]	During the six months ended June 30, 2014, pursuant to the terms of certain notes payable with maturity dates ranging from January 8, 2014 to March 18, 2014, the principal balances of the notes were increased from an aggregate of $60,000 to $71,250. The aggregate $11,250 of principal increases was accreted as interest expense.
		[3]	On April 1, 2014, in connection with the extension of certain notes payable with maturity dates ranging from August 8, 2013 to December 6, 2013 to new maturity dates ranging from October 1, 2014 to April 1, 2015, an aggregate of  $73,058 of accrued interest was added to the principal balance of the notes, increasing the aggregate principal balance from $652,500 to $725,558.
		[4]	As of June 30, 2014, a Convertible Note with a principal balance of $26,669 was convertible at the election of the holder.

Stockholders_Deficiency_Tables

Stockholders' Deficiency (Tables)	6 Months Ended
	Jun. 30, 2014
Stockholders' Equity Note [Abstract]	'
Black-Scholes Option Pricing Model to Warrants Granted, Weighted Average Assumptions	'
	In applying the Black-Scholes option pricing model to warrants granted, the Company used the following weighted average assumptions:
			For the Three Months Ended				For the Six Months Ended
			June 30,				June 30,
			2014		2013		2014		2013
	Risk free interest rate		1.64	%	0.93	%	1.58	%	0.81	%
	Expected term (years)		5		5		4.78		4.98
	Expected volatility		120	%	135	%	120	%	135	%
	Expected dividends		0	%	0	%	0	%	0	%
Summary of Warrant Activity	'
	A summary of the stock warrant activity during the six months ended June 30, 2014 is presented below:
									Weighted
					Weighted				Average
					Average				Remaining
			Number of		Exercise				Life		Intrinsic
			Warrants		Price				In Years		Intrinsic
	Outstanding, December 31, 2013		4,795,890		$	1.39
	Granted		1,796,528			0.74
	Exercised		-266,667			0.3	[1]
	Forfeited		-			-
	Outstanding, June 30, 2014		6,325,751		$	1.05			3.2		$	-
	Exercisable, June 30, 2014		5,625,751		$	0.99			3.2		$	-
	[1]	Warrants to purchase an aggregate of 266,667 shares of common stock had their exercise prices reduced to $0.30 per share pursuant to the Warrant Exercise and Reload Program. The warrants previously had exercise prices that ranged from $1.50 to $4.00 per share. See Note 7 – Stockholders’ Deficiency – Warrant Exercise and Reload Program.
Information Related to Stock Warrants	'
	The following table presents information related to stock warrants at June 30, 2014:
	Warrants Outstanding						Warrants Exercisable
							Weighted
							Average		Exercisable
	Exercise				Number of		Remaining Life		Number of
	Price				Warrants		In Years		Warrants
	$	0.3			650,000		4.9		650,000
		0.5			40,000		0.1		40,000
		0.53			380,000		3.9		380,000
		0.75			2,632,557		2.3		2,632,557
		0.94			50,000		4.4		50,000
		1			550,000		4.9		550,000
		1.5			862,800		3		862,800
		1.75			70,000		3.6		70,000
		2			123,530		4.4		123,530
		2.5			60,000		3		60,000
		3			36,864		3.8		36,864
		4			170,000		3.6		170,000
		Variable	[2]		700,000		-		-
					6,325,751		3.2		5,625,751
	[2]	Warrants to purchase 700,000 shares of common stock have an exercise price which is the greater of $1.50 per share or the fair market value of the common stock on the date certain performance criteria are met. Exercisability of warrants is subject to satisfaction of certain performance criteria which did not occur during the six months ended June 30, 2014.
Black-Scholes Option Pricing Model to Stock Options Granted, Weighted Average Assumptions	'
	In applying the Black-Scholes option pricing model to stock options granted, the Company used the following weighted average assumptions:
			For the Three Months Ended						For the Six Months Ended
			June 30,						June 30,
			2014			2013			2014			2013
	Risk free interest rate		1.93	%		1.13	%		1.61	%		1.81	%
	Expected term (years)		6.88			5			5.81			9.62
	Expected volatility		120	%		135	%		120	%		135	%
	Expected dividends		0	%		0	%		0	%		0	%
Stock option expense	'
	The following table presents information related to stock option expense:
																	Weighted
																	Average
			For The Three Months Ended						For The Six Months Ended					Unrecognized			Amortization
			June 30,						June 30,					at June 30,			Period
			2014			2013			2014			2013		2014			(Years)
	Consulting		$	150,962		$	19,125		$	251,575		$	64,250	$	166,128	[1]		1.8
	Research and development			32,324			40,127			153,714			123,859		193,573	[2]		1.8
	General and administrative			21,280			52,681			104,979			106,431		151,659			1.6
			$	204,566		$	111,933		$	510,268		$	294,540	$	511,360			1.8
		[1]	Includes $8,363 of unrecognized expense that is subject to non-employee mark-to-market adjustments.
		[2]	Includes $152,710 of unrecognized expense that is subject to non-employee mark-to-market adjustments.
Summary of Option Activity	'
	A summary of the stock option activity during the six months ended June 30, 2014 is presented below:
									Weighted
						Weighted			Average
						Average			Remaining
			Number of			Exercise			Life			Intrinsic
			Options			Price			In Years			Value
	Outstanding, December 31, 2013			5,043,000		$	1.03
	Granted			3,700,000			0.55
	Exercised			-			-
	Forfeited			-34,000			1.31
	Outstanding, June 30, 2014			8,709,000		$	0.83			8.4		$	13,500
	Exercisable, June 30, 2014			5,323,167		$	0.97			7.4		$	3,000
Information Related to Stock Options	'
	The following table presents information related to stock options at June 30, 2014:
	Options Outstanding						Options Exercisable
							Weighted
				Outstanding			Average			Exercisable
		Exercise		Number of			Remaining Life			Number of
		Price		Options			In Years			Options
	$	0.285			900,000			10			200,000
		0.39			60,000			-			-
		0.5			345,000			5.4			332,500
		0.53			40,000			9.7			40,000
		0.6			980,000			9.3			490,000
		0.65			2,675,000			5.6			791,667
		1			131,000			8.1			81,000
		1.05			2,270,000			7.6			2,270,000
		1.1			5,000			2.9			5,000
		1.2			10,000			1.9			10,000
		1.25			43,000			2.4			43,000
		1.4			350,000			5.4			160,000
		1.5			900,000			8.4			900,000
					8,709,000			7.4			5,323,167
Common Stock Award Expense	'
	The following table presents information related to common stock award expense:
			For The Three Months Ended						For The Six Months Ended					Unrecognized
			June 30,						June 30,					at June 30,
			2014			2013			2014			2013		2014
	Consulting		$	224,500		$	6,001		$	234,500		$	54,001	$	-
	Research and development			1,827			-			5,898			723		-
	General and administrative			-			-			-			-		-
			$	226,327		$	6,001		$	240,398		$	54,724	$	-
Summary of Common Stock Award Activity	'
	A summary of common stock award activity for the six months ended June 30, 2014 is presented below:
						Weighted
						Average			Total
			Number of			Grant Date			Grant Date
			Shares			Fair Value			Fair Value
	Non-vested, December 31, 2013			-		$	-		$	-
	Granted			878,458			0.27			240,398
	Vested			-878,458			-0.27			-240,398
	Forfeited			-			-			-
	Non-vested, June 30, 2014			-		$	-		$	-

Going_Concern_and_Management_P1

Going Concern and Management Plans - Additional Information (Detail) (USD $)	3 Months Ended		6 Months Ended
	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013	Dec. 31, 2013
Organization, Consolidation and Presentation of Financial Statements Disclosure [Line Items]	'	'	'	'	'
Working capital deficiency	$8,163,102	'	$8,163,102	'	'
Stockholders deficiency	-7,148,786	'	-7,148,786	'	-6,685,069
Net loss	-1,333,139	-1,251,195	-3,002,815	-2,817,193	'
Amount raised through equity financing	'	'	205,000	'	'
Notes payable aggregate principal past due	244,063	'	244,063	'	'
Other Research and Development Expense	'	'	89,063	'	'
Debt Instrument, Increase, Accrued Interest	'	'	35,000	'	'
Other Notes Payable, Total	4,000,000	'	4,000,000	'	'
Note principal and accrued interest converted to equity	'	'	-274,000	'	'
Financing Receivable	'	'	'	'	'
Organization, Consolidation and Presentation of Financial Statements Disclosure [Line Items]	'	'	'	'	'
Other Research and Development Expense	'	'	0	'	'
Repayments of Debt	'	'	0	'	'
Debt Instrument, Increase, Accrued Interest	'	'	0	'	'
Research and Development Expense	'	'	'	'	'
Organization, Consolidation and Presentation of Financial Statements Disclosure [Line Items]	'	'	'	'	'
Repayments of Debt	'	'	0	'	'
Debt Instrument, Increase, Accrued Interest	'	'	0	'	'
Notes Payable, Accrued Interest Exchanged	'	'	'	'	'
Organization, Consolidation and Presentation of Financial Statements Disclosure [Line Items]	'	'	'	'	'
Note principal and accrued interest converted to equity	'	'	2,992	'	'
Notes Payable, Principal Exchanged	'	'	'	'	'
Organization, Consolidation and Presentation of Financial Statements Disclosure [Line Items]	'	'	'	'	'
Note principal and accrued interest converted to equity	'	'	$76,669	'	'

Summary_of_Significant_Account3

Summary of Significant Accounting Policies - Additional Information (Detail) (USD $)

0 Months Ended

3 Months Ended

6 Months Ended

3 Months Ended

6 Months Ended

0 Months Ended

3 Months Ended

6 Months Ended

Mar. 19, 2014

Jun. 30, 2014

Jun. 30, 2013

Jun. 30, 2014

Jun. 30, 2013

Dec. 31, 2013

Jun. 30, 2014

Jun. 30, 2014

Dec. 31, 2013

Mar. 24, 2014

Jun. 30, 2014

Jun. 30, 2014

Jun. 30, 2013

Jun. 30, 2014

Jun. 30, 2013

Research and development agreements

Research and development agreements

Research and Development Agreements One-Year

Research and Development Agreements Two-Year

Research and Development Agreements Two-Year

Stem Pearls Skincare Products

Stem Pearls Skincare Products

Stem Pearls Skincare Products

Stem Pearls Skincare Products

Summary Of Significant Accounting Policies [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Debt instrument outstanding face amount percentage

'

75.00%

'

75.00%

'

'

'

'

'

'

'

'

'

'

'

Debt Instrument, Payment Terms

'Payment terms are (1) $150,000 at commencement; (2) $50,000 upon achievement of a specified deliverable; and (3) $50,000 upon achievement of the final specified deliverable.

'

'

'

'

'

'

'

'

'Payment terms are (1) $250,000 at commencement; (2) $356,250 payable in four equal quarterly installments, subject to acceleration upon achieving a specified deliverable; and (3) $168,750 payable in two equal bi-annual installments, subject to acceleration upon achieving a specified deliverable.

'

'

'

'

'

Deferred Revenue, Current

'

$224,975

'

$224,975

'

$0

'

'

$79,281

'

$145,694

'

'

'

'

Revenue, Net

'

'

'

'

'

'

'

'

'

'

'

916

425

1,291

1,555

Revenues

'

$175,941

$425

$176,316

$1,555

'

$175,025

$175,025

'

'

'

'

'

'

'

Calculation_of_Weighted_Averag

Calculation of Weighted Average Dilutive Common Shares (Detail)	6 Months Ended
	Jun. 30, 2014	Jun. 30, 2013
Exclusion Of Securities [Line Items]	'	'
Total potentially dilutive shares	16,516,844	8,333,890
Convertible Notes	'	'
Exclusion Of Securities [Line Items]	'	'
Total potentially dilutive shares	1,482,093	0
Options	'	'
Exclusion Of Securities [Line Items]	'	'
Total potentially dilutive shares	8,709,000	3,963,000
Warrants	'	'
Exclusion Of Securities [Line Items]	'	'
Total potentially dilutive shares	6,325,751	4,370,890

Accrued_Expenses_and_Other_Cur2

Accrued Expenses and Other Current Liabilities - Additional Information (Detail) (USD $)	6 Months Ended
	Jun. 30, 2014	Jun. 30, 2013
Accrued Expenses and Other Current Liabilities [Line Items]	'	'
Advances from officer	$15,015	$75,385
Repayment of advances from officer	40,005	69,370
Liability to officer	'	$6,015

Accrued_Expenses_and_Other_Cur3

Accrued Expenses and Other Current Liabilities (Detail) (USD $)	Jun. 30, 2014	Dec. 31, 2013
Accrued Expenses and Other Current Liabilities [Line Items]	'	'
Credit card payable	$4,772	$6,000
Accrued payroll and payroll taxes	757,205	672,535
Other accrued expenses	393,989	495,817
Deferred rent	0	2,310
Total	$1,155,966	$1,176,662

Notes_Payable_Additional_Infor

Notes Payable - Additional Information (Detail) (USD $)

3 Months Ended

6 Months Ended

1 Months Ended

6 Months Ended

0 Months Ended

3 Months Ended

6 Months Ended

3 Months Ended

6 Months Ended

Jun. 30, 2014

Mar. 31, 2014

2-May-14

Jun. 30, 2013

Jun. 30, 2014

Jun. 30, 2013

Jun. 30, 2014

Jun. 30, 2014

Jun. 27, 2014

Jun. 30, 2014

Jun. 30, 2014

Jun. 30, 2014

Mar. 10, 2014

2-May-14

Jun. 30, 2014

Jun. 30, 2014

2-May-14

Jun. 30, 2014

Jun. 30, 2014

Jun. 30, 2014

Jun. 30, 2014

8-May-14

Lender

Notes Payable

Marketing Consulting Services

Minimum

Maximum

In exchange of notes payable

Convertible Notes Payable

Convertible Notes Payable

Convertible Notes Payable

Convertible Notes Payable

Convertible Notes Payable

Convertible Notes Payable

Convertible Notes

Convertible Notes

Convertible Notes

Bermuda Lender

Minimum

Maximum

Maximum

Minimum

Maximum

Debt Instrument [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Aggregate principal amount

'

'

'

'

'

'

'

$76,669

'

'

'

'

'

'

'

'

'

'

'

'

'

$500,000

Rate of interest

'

'

12.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Loss on settlement of note and payables, net

0

'

'

0

49,094

7,200

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common stock aggregate grant date fair value

330,436

'

'

'

330,436

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Debt instrument, new proceeds

'

'

'

'

'

'

'

'

'

'

'

'

'

170,000

'

'

'

'

'

'

'

'

Debt Instrument Annual Principal Payment

752,500

'

30,000

'

752,500

'

'

'

'

'

'

'

30,000

'

100,000

'

'

'

57,081

'

'

'

Debt Instrument issued for consideration

'

'

25,000

'

'

'

'

'

'

'

'

'

25,000

'

'

'

'

'

'

'

'

'

Debt Instrument Periodic Payment Interest

'

9,934

5,000

'

11,250

'

'

'

'

'

'

'

5,000

'

73,058

'

'

'

'

'

'

'

Debt Instrument, Periodic Payment, Principal

'

'

145,000

'

26,669

'

'

'

'

652,500

725,558

'

'

'

'

'

'

'

'

'

'

'

Proceeds from Notes Payable

'

'

'

'

670,000

563,000

'

'

'

'

'

0

'

'

175,000

[1]

'

175,000

'

'

'

'

'

Debt Instrument, Convertible, Beneficial Conversion Feature

'

'

145,000

'

41,384

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Debt Instrument, Increase, Accrued Interest

'

'

'

'

35,000

'

'

'

'

60,000

71,250

'

'

'

6,187

'

'

'

3,500

'

'

'

Debt instrument, interest rate, effective percentage

'

'

79.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

15.00%

Payments under Research and Development Agreements

53,000

'

'

'

53,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures, Total

'

'

'

'

11,219

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Stock Issued During Period, Value, Issued in Exchange of Notes Payable, Principal Amount

'

'

'

'

274,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Stock Issued During Period, Value, Issued in Exchange of Notes Payable, Interest Amount

'

'

'

'

19,932

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Stock Issued During Period, Shares, Issued in Exchange of Notes Payable

'

'

'

'

1,101,453

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Warrants Issued During Period, Number of Warrants

'

'

'

'

100,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Warrant exercise price

$0.75

'

'

'

$0.75

'

'

'

'

$1.75

$2.50

'

'

'

'

'

'

'

'

'

'

'

Proceeds from Convertible Debt

'

'

'

'

0.75

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Debt instrument issue description

'

'

'

'

'(a) 55%-60%, depending on the particular note, of the fair value of the Companys stock or (b) $0.05 per share. The remaining $30,000 is convertible into shares of the Companys common stock at the election of the holder any time after September 10, 2014 at the lesser of (a) $0.50 per share or (b) 65% of the fair value of the Companys common stock, but with a floor of $0.05 per share.

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Warrant aggregate grant date fair value

12,590

'

'

'

12,590

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Debt Instrument, Maturity Date

'

'

'

'

'

'

'

'

'

8-Jan-14

18-Mar-14

'

'

'

'

'

'

'

'

'

'

'

Conversion of Stock, Shares Issued

'

'

'

'

'

'

'

'

'

'

'

'

'

'

442,778

'

'

'

282,685

'

'

'

Debt Instrument, Convertible, Conversion Price

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$0.20

'

$0.28

'

$0.20

$0.22

'

Debt Instrument, Interest Rate, Stated Percentage Rate Range, Minimum

'

'

'

'

8.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Debt Instrument, Interest Rate, Stated Percentage Rate Range, Maximum

'

'

'

'

15.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Debt Instrument, Increase (Decrease), Other, Net

'

'

'

'

73,058

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding, Number

100,000

'

'

'

100,000

'

50,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Class of Warrant or Right, Outstanding

90,000

'

'

'

90,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Consulting Expense

'

'

'

'

'

'

'

'

$65,000

'

'

'

'

'

'

'

'

'

'

'

'

'

Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percent

'

'

'

'

175.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

[1]

On March 10, 2014, a note with a principal amount of $30,000 was issued for cash consideration of $25,000 and bears no interest. The $5,000 difference was recorded as debt discount and will be accreted as interest expense over the term of the note. During the six months ended June 30, 2014, the Company accreted interest expense of $9,934 related to notes issued for cash consideration less than the principal amounts.

Notes_Payable_Detail

Notes Payable (Detail) (USD $)	3 Months Ended			6 Months Ended
	Jun. 30, 2014		Jun. 30, 2013	Jun. 30, 2014		Jun. 30, 2013
Debt Instrument [Line Items]	'		'	'		'
Balance	'		'	$4,990,009		'
Issuances	'		'	670,000		563,000
Exchanges for equity	'		'	-274,000		'
Conversions to equity	'		'	-157,081		'
Repayments	'		'	-53,000		0
Setup of debt discount	'		'	-61,384		'
Amortization of debt discount	145,930		105,282	244,435		166,631
Accretion of interest expense	'		'	94,242		'
Balance	5,905,552		'	5,905,552		'
Debt Discount	'		'	'		'
Debt Instrument [Line Items]	'		'	'		'
Balance	'		'	-240,491		'
Issuances	'		'	0		'
Exchanges for equity	'		'	0		'
Conversions to equity	'		'	0		'
Repayments	'		'	0		'
Setup of debt discount	'		'	-61,384		'
Amortization of debt discount	'		'	244,435		'
Accretion of interest expense	'		'	9,934	[1]	'
Balance	-47,506		'	-47,506		'
Convertible Notes Payable	'		'	'		'
Debt Instrument [Line Items]	'		'	'		'
Balance	'		'	281,000		'
Issuances	'		'	175,000	[1]	'
Exchanges for equity	'		'	-71,000		'
Conversions to equity	'		'	-157,081		'
Repayments	'		'	0		'
Setup of debt discount	'		'	0		'
Amortization of debt discount	'		'	0		'
Accretion of interest expense	'		'	11,250	[2]	'
Balance	239,169	[3]	'	239,169	[3]	'
Notes Payable, Other Payables	'		'	'		'
Debt Instrument [Line Items]	'		'	'		'
Balance	'		'	1,473,500		'
Issuances	'		'	0		'
Exchanges for equity	'		'	-203,000		'
Conversions to equity	'		'	0		'
Repayments	'		'	-53,000		'
Setup of debt discount	'		'	0		'
Amortization of debt discount	'		'	0		'
Accretion of interest expense	'		'	73,058	[4]	'
Balance	1,290,558		'	1,290,558		'
Bermuda Lender Member	'		'	'		'
Debt Instrument [Line Items]	'		'	'		'
Balance	'		'	4,000,000		'
Issuances	'		'	500,000		'
Exchanges for equity	'		'	0		'
Conversions to equity	'		'	0		'
Repayments	'		'	0		'
Setup of debt discount	'		'	0		'
Amortization of debt discount	'		'	0		'
Accretion of interest expense	'		'	0		'
Balance	$4,500,000		'	$4,500,000		'
[1]	On March 10, 2014, a note with a principal amount of $30,000 was issued for cash consideration of $25,000 and bears no interest. The $5,000 difference was recorded as debt discount and will be accreted as interest expense over the term of the note. During the six months ended June 30, 2014, the Company accreted interest expense of $9,934 related to notes issued for cash consideration less than the principal amounts.
[2]	During the six months ended June 30, 2014, pursuant to the terms of certain notes payable with maturity dates ranging from January 8, 2014 to March 18, 2014, the principal balances of the notes were increased from an aggregate of $60,000 to $71,250. The aggregate $11,250 of principal increases was accreted as interest expense.
[3]	As of June 30, 2014, a Convertible Note with a principal balance of $26,669 was convertible at the election of the holder.
[4]	On April 1, 2014, in connection with the extension of certain notes payable with maturity dates ranging from August 8, 2013 to December 6, 2013 to new maturity dates ranging from October 1, 2014 to April 1, 2015, an aggregate of $73,058 of accrued interest was added to the principal balance of the notes, increasing the aggregate principal balance from $652,500 to $725,558.

Commitments_and_Contingencies_

Commitments and Contingencies - Additional Information (Detail) (USD $)

1 Months Ended

3 Months Ended

6 Months Ended

6 Months Ended

0 Months Ended

1 Months Ended

0 Months Ended

6 Months Ended

1 Months Ended

6 Months Ended

1 Months Ended

6 Months Ended

1 Months Ended

1 Months Ended

Jun. 27, 2014

Feb. 20, 2014

Nov. 30, 2013

Jun. 30, 2014

2-May-14

Jun. 30, 2013

Jun. 30, 2014

Jun. 30, 2013

Mar. 14, 2014

Jun. 30, 2014

Jun. 27, 2014

Mar. 31, 2014

Mar. 14, 2014

Feb. 20, 2014

Mar. 14, 2014

Mar. 14, 2014

Mar. 14, 2014

Feb. 04, 2014

Jun. 30, 2014

Jun. 30, 2014

Jun. 27, 2014

Jun. 30, 2014

Jun. 27, 2014

Jun. 27, 2014

Jun. 30, 2014

Mar. 31, 2014

Jun. 27, 2014

Jun. 27, 2014

Jun. 27, 2014

Jun. 27, 2014

Jun. 27, 2014

Jun. 27, 2014

Mar. 31, 2014

Mar. 12, 2014

Mar. 12, 2014

Mar. 12, 2014

Warrants

Warrants

Warrants

Convertible Notes Payable One

Chief Medical Advisor

Scientific Advisory Board

Scientific Advisory Board

Scientific Advisory Board

Florida Leased Premises

Minimum

Maximum

Director

Consultant

Board Of Directors

Research and Development Arrangement

Research and Development Arrangement

Research and Development Arrangement

Research and Development Arrangement

Research and Development Arrangement

Marketing Consulting Services Agreement

Marketing Consulting Services Agreement

Business Advisory Services

Scientific Advisory Services

Stem Cell Treatment Company [Member]

Warrants Issue One

Warrants Issue Two

Warrants Issue Three

Immediately Vesting

Vesting Over One Year

Minimum

Maximum

Warrants

Consultant

Consultant

Consultant

Commitments and Contingencies Disclosure [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Stock issued during period shares for services

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

378,458

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Stock issued during period, value, issued for services

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$130,398

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Stock-based compensation, stock option granted

'

'

'

'

'

'

3,700,000

'

'

'

'

'

25,000

300,000

5,000

12,500

12,500

'

'

'

'

'

'

'

'

'

'

'

'

'

'

300,000

'

'

'

'

Common stock exercise price

'

'

'

'

'

'

$0.55

'

'

'

'

'

'

$0.65

$0.50

'

'

'

'

'

'

$0.75

'

'

'

'

'

'

'

'

'

$0.28

'

'

'

'

Monthly payments for leasing

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

962

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Payments for leasing per day

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

100

'

'

'

Payments for leasing costs

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

3,750

'

'

'

Monthly Payments under Consulting Agreements

'

'

'

'

'

'

'

'

'

'

'

'

'

10,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Monthly Escalating Payments under Consulting Agreements

'

'

'

'

'

'

'

'

'

'

'

'

'

20,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Warrants Issued During Period, Number of Warrants

'

'

'

'

'

'

100,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

100,000

280,000

20,000

Warrants Issued During Period, Exercise Price at Issuance Date

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$0.53

$0.53

$1.50

Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period

'

'3 years

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Share Based Compensation Arrangement By Share Based Payment Award Grant Date Fair Value

'

67,830

'

'

'

'

'

'

5,860

'

110,000

23,360

'

'

'

'

'

'

'

'

144,000

'

'

'

'

'

'

'

'

37,500

37,500

81,000

'

'

'

'

Allocated Share-Based Compensation Expense

'

'

'

'

'

'

'

'

'

30,366

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Rent expenses

'

'

'

4,000

'

16,000

14,000

52,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Stock-based compensation

'

'

'

'

'

'

917,792

369,868

'

'

'

'

'

'

'

'

'

'

'

'

'

'

96,250

'

'

'

'

'

'

'

'

'

'

'

'

'

Loss Contingency, Damages Paid, Value

'

'

193,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Loss Contingency Damages Paid Value Warrants Issued

'

'

80,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Consulting Expense In Shares

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

500,000

'

'

'

'

'

'

'

Warrant Issued To Purchase Common Stock

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

600,000

'

'

'

'

'

'

'

250,000

'

250,000

'

'

'

'

'

Investment Warrant Exercise Price

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$1

'

$1

'

'

'

'

'

Warrant To Purchase Common Stock Issued In Period Contractual Term

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'5 years

'

'5 years

'10 years

'

'

'

'

Professional Fees Payable Per Month

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

20,000

41,667

'

'

16,667

'

'

'

'

'

Additional Professional Fees Payable

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

10,000

'

'

'

'

Number Of Shares Immediately Vest On Date Of Grants

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

150,000

'

'

'

'

Number Of Shares Vest On Second Anniversary Of Date Of Grant

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

200,000

'

'

'

'

'

'

'

'

'

'

150,000

'

'

'

'

Professional Fees

'

'

'

557,565

'

140,389

824,763

370,505

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

323,336

208,335

'

'

'

'

'

'

'

'

'

'

'

Agreement Expiration Date

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

15-Jun-12

'

'

'

'

'

'

'

'

'

'

'

'

Compensation Paid To Directors Aggregate Amount

30,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Compensation Paid To Directors Installment Amount

50,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Stock Options Granted Exercise Price Per Share

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$0.28

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Number Of Shares Vest On First Anniversary Of Date Of Grant

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

200,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Number Of Shares Vest On Third Anniversary Of Date Of Grant

200,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Salaries, Wages and Officers' Compensation

80,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Debt Instrument, Periodic Payment, Principal

'

'

'

'

145,000

'

26,669

'

'

'

'

'

'

'

'

'

'

'

652,500

725,558

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Accrued Professional Fees

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

104,168

'

'

'

'

'

'

'

'

'

'

Accrued Salaries

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$50,000

'

'

'

'

'

'

'

'

'

'

'

'

'

Stockholders_Deficiency_Additi

Stockholders' Deficiency - Additional Information (Detail) (USD $)

0 Months Ended

3 Months Ended

6 Months Ended

1 Months Ended

6 Months Ended

1 Months Ended

0 Months Ended

3 Months Ended

6 Months Ended

3 Months Ended

6 Months Ended

1 Months Ended

6 Months Ended

1 Months Ended

6 Months Ended

1 Months Ended

Jun. 16, 2014

Jun. 30, 2014

Jun. 30, 2013

Jun. 30, 2014

Jun. 30, 2013

Mar. 12, 2014

Dec. 31, 2013

Nov. 27, 2013

Jun. 30, 2014

Jun. 30, 2014

Jun. 30, 2014

Jun. 30, 2014

Mar. 12, 2014

Mar. 12, 2014

Jun. 16, 2014

Jun. 30, 2014

Jun. 30, 2013

Jun. 30, 2014

Jun. 30, 2013

Jun. 30, 2014

Jun. 30, 2014

Jun. 30, 2013

Jun. 30, 2014

Jun. 30, 2013

Jun. 30, 2014

Mar. 12, 2014

Jun. 30, 2014

Jun. 30, 2014

Jun. 30, 2014

Feb. 18, 2014

Mar. 12, 2014

Jun. 30, 2014

Feb. 18, 2014

Mar. 12, 2014

Warrant Exercise and Reload Program

Warrant Exercise and Reload Program

Exercise Price Dollor One Point Five Zero

Exercise Price Dollor Zero Point Three Zero

Treasury Stock [Member]

Second Anniversary of Grant Date

Employees and Directors

Employees, Directors and an Advisor

Warrants

Warrants

Warrants

Warrants

Consultant Awards

Consultant Awards

Consultant Awards

Consultant Awards

Consultant Awards

Consultant Awards

Employee Awards

Common Stock

Common Stock Issuance

Minimum

Minimum

Minimum

Maximum

Maximum

Maximum

Research and Development Expense [Member]

Warrants

Warrants

Warrants

Warrants

Non Employee Stock Options

Employees and Directors

Employees and Directors

Stockholders Equity Note Disclosure [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Stock issued (in shares)

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

2,968,651

'

'

'

'

'

'

Warrants to purchase common stock

'

266,667

'

266,667

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Warrants exercise price

'

'

'

'

'

'

'

'

$0.30

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$1.50

'

'

$4

'

'

Estimated Forfeitures Related To Option Grants Annual Rate

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0.00%

'

'

5.00%

'

'

Weighted average estimated fair value of stock warrants granted, per share

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$0.16

$0.36

$0.19

$0.63

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Stock-based compensation expense

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$113,400

$3,596

$167,126

$20,604

'

'

'

'

'

'

'

'

'

'

Unrecognized stock-based compensation expense

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

152,710

'

'

'

'

8,363

'

'

'

'

'

'

'

'

'

Share granted vested

'

'

'

'

'

831,669

'

'

'

'

'

'

1,589,331

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Weighted average estimated fair value of stock options granted

'

$0.25

$0.41

$0.24

$0.74

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Stock-based compensation, stock option granted

'

'

'

3,700,000

'

'

'

'

'

'

'

'

'

2,415,000

60,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Stock-based compensation, stock options granted, exercise price

'

'

'

$0.55

'

'

'

'

'

'

'

'

'

'

$0.39

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$0.53

'

'

$0.65

Stock-based compensation, stock options granted, grant date fair value

18,600

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

566,483

'

'

'

'

'

'

'

'

Common stock, Authorized

'

100,000,000

'

100,000,000

'

'

100,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

6,000,000

'

'

12,000,000

'

Warrant modification charge

'

0

'

30,128

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Warrants excluded from computation of weighted average price of warrants granted

'

'

'

'

'

'

'

'

'

700,000

266,667

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Share based compensation shares authorized under stock option plans exercise price

'

'

'

'

'

'

'

'

'

$1.50

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Sale of Stock, Price Per Share

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$0.25

'

'

$0.45

'

'

Stock Issued During Period, Value, New Issues

'

'

'

15,000

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

945,000

'

'

'

'

'

'

'

Warrants Issued During Period, Number of Warrants

'

'

'

100,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

729,861

'

'

'

'

'

'

'

Warrants Issued During Period, Number of Warrants1

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$0.30

'

'

$0.75

'

'

Description on newly issued Warrant

'

'

'

'

'

'

'

'The terms of the newly issued warrant permit the Company to redeem the new warrant for a total of $1.00 if the common stock of the Company trades above $1.25 for five consecutive trading days.

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Proceeds from Issuance of Common Stock

'

'

'

$80,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

BlackScholes_Option_Pricing_Mo

Black-Scholes Option Pricing Model to Warrant Granted, Weighted Average Assumptions (Detail) (Warrants)	3 Months Ended		6 Months Ended
	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013
Warrants	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'
Risk free interest rate	1.64%	0.93%	1.58%	0.81%
Expected term (years)	'5 years	'5 years	'4 years 9 months 11 days	'4 years 11 months 23 days
Expected volatility	120.00%	135.00%	120.00%	135.00%
Expected dividends	0.00%	0.00%	0.00%	0.00%

Summary_of_Warrant_Activity_De

Summary of Warrant Activity (Detail) (Warrants, USD $)	6 Months Ended
	Jun. 30, 2014
Warrants	'
Number of Warrants	'
Beginning Balance	4,795,890
Granted	1,796,528
Exercised	-266,667
Forfeited	0
Ending Balance	6,325,751
Exercisable	5,625,751
Weighted Average Exercise Price	'
Beginning Balance	$1.39
Granted	$0.74
Exercised	$0.30	[1]
Forfeited	$0
Ending Balance	$1.05
Exercisable	$0.99
Weighted Average Remaining Life (In Years)	'
Outstanding	'3 years 2 months 12 days
Exercisable	'3 years 2 months 12 days
Intrinsic Value	'
Outstanding	$0
Exercisable	$0
[1]	Warrants to purchase an aggregate of 266,667 shares of common stock had their exercise prices reduced to $0.30 per share pursuant to the Warrant Exercise and Reload Program. The warrants previously had exercise prices that ranged from $1.50 to $4.00 per share. See Note 7 B Stockholdersb Deficiency B Warrant Exercise and Reload Program.

Summarized_Information_Related

Summarized Information Related to Stock Warrants (Detail) (USD $)	6 Months Ended
	Jun. 30, 2014
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'
Warrants Outstanding, Number of Warrants	6,325,751
Warrants Exercisable, Weighted Average Remaining Life In Years	'3 years 2 months 12 days
Warrants Exercisable, Exercisable Number of Warrants	5,625,751
Exercise Price 1	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'
Warrants Outstanding, Exercise Price	0.3
Warrants Outstanding, Number of Warrants	650,000
Warrants Exercisable, Weighted Average Remaining Life In Years	'4 years 10 months 24 days
Warrants Exercisable, Exercisable Number of Warrants	650,000
Exercise Price 2	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'
Warrants Outstanding, Exercise Price	0.5
Warrants Outstanding, Number of Warrants	40,000
Warrants Exercisable, Weighted Average Remaining Life In Years	'1 month 6 days
Warrants Exercisable, Exercisable Number of Warrants	40,000
Exercise Price 3	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'
Warrants Outstanding, Exercise Price	0.53
Warrants Outstanding, Number of Warrants	380,000
Warrants Exercisable, Weighted Average Remaining Life In Years	'3 years 10 months 24 days
Warrants Exercisable, Exercisable Number of Warrants	380,000
Exercise Price 4	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'
Warrants Outstanding, Exercise Price	0.75
Warrants Outstanding, Number of Warrants	2,632,557
Warrants Exercisable, Weighted Average Remaining Life In Years	'2 years 3 months 18 days
Warrants Exercisable, Exercisable Number of Warrants	2,632,557
Exercise Price 5	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'
Warrants Outstanding, Exercise Price	0.94
Warrants Outstanding, Number of Warrants	50,000
Warrants Exercisable, Weighted Average Remaining Life In Years	'4 years 4 months 24 days
Warrants Exercisable, Exercisable Number of Warrants	50,000
Exercise Price 6	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'
Warrants Outstanding, Exercise Price	1
Warrants Outstanding, Number of Warrants	550,000
Warrants Exercisable, Weighted Average Remaining Life In Years	'4 years 10 months 24 days
Warrants Exercisable, Exercisable Number of Warrants	550,000
Exercise Price 7	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'
Warrants Outstanding, Exercise Price	1.5
Warrants Outstanding, Number of Warrants	862,800
Warrants Exercisable, Weighted Average Remaining Life In Years	'3 years
Warrants Exercisable, Exercisable Number of Warrants	862,800
Exercise Price 8	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'
Warrants Outstanding, Exercise Price	1.75
Warrants Outstanding, Number of Warrants	70,000
Warrants Exercisable, Weighted Average Remaining Life In Years	'3 years 7 months 6 days
Warrants Exercisable, Exercisable Number of Warrants	70,000
Exercise Price 9	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'
Warrants Outstanding, Exercise Price	2
Warrants Outstanding, Number of Warrants	123,530
Warrants Exercisable, Weighted Average Remaining Life In Years	'4 years 4 months 24 days
Warrants Exercisable, Exercisable Number of Warrants	123,530
Exercise Price 10	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'
Warrants Outstanding, Exercise Price	2.5
Warrants Outstanding, Number of Warrants	60,000
Warrants Exercisable, Weighted Average Remaining Life In Years	'3 years
Warrants Exercisable, Exercisable Number of Warrants	60,000
Exercise Price 11	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'
Warrants Outstanding, Exercise Price	3
Warrants Outstanding, Number of Warrants	36,864
Warrants Exercisable, Weighted Average Remaining Life In Years	'3 years 9 months 18 days
Warrants Exercisable, Exercisable Number of Warrants	36,864
Exercise Price 12	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'
Warrants Outstanding, Exercise Price	4
Warrants Outstanding, Number of Warrants	170,000
Warrants Exercisable, Weighted Average Remaining Life In Years	'3 years 7 months 6 days
Warrants Exercisable, Exercisable Number of Warrants	170,000
Exercise Price 13	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'
Warrants outstanding, Exercise Price Description	'Variable	[1]
Warrants Outstanding, Number of Warrants	700,000
Warrants Exercisable, Weighted Average Remaining Life In Years	'0 years
Warrants Exercisable, Exercisable Number of Warrants	0
[1]	Warrants to purchase 700,000 shares of common stock have an exercise price which is the greater of $1.50 per share or the fair market value of the common stock on the date certain performance criteria are met. Exercisability of warrants is subject to satisfaction of certain performance criteria which did not occur during the six months ended June 30, 2014.

BlackScholes_Option_Pricing_Mo1

Black-Scholes Option Pricing Model to Stock Option Granted, Weighted Average Assumptions (Detail) (Stock Options)	3 Months Ended		6 Months Ended
	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013
Stock Options	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'
Risk free interest rate	1.93%	1.13%	1.61%	1.81%
Expected term (years)	'6 years 10 months 17 days	'5 years	'5 years 9 months 22 days	'9 years 7 months 13 days
Expected volatility	120.00%	135.00%	120.00%	135.00%
Expected dividends	0.00%	0.00%	0.00%	0.00%

Information_Related_to_Stock_O

Information Related to Stock Option Expense (Detail) (Stock Options, USD $)	3 Months Ended			6 Months Ended
	Jun. 30, 2014		Jun. 30, 2013	Jun. 30, 2014		Jun. 30, 2013
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]	'		'	'		'
Stock-based compensation expense	$204,566		$111,933	$510,268		$294,540
Unrecognized expense	511,360		'	511,360		'
Weighted Average Amortization Period (Years)	'		'	'1 year 9 months 18 days		'
Consulting	'		'	'		'
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]	'		'	'		'
Stock-based compensation expense	150,962		19,125	251,575		64,250
Unrecognized expense	166,128	[1]	'	166,128	[1]	'
Weighted Average Amortization Period (Years)	'		'	'1 year 9 months 18 days		'
Research and development	'		'	'		'
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]	'		'	'		'
Stock-based compensation expense	32,324		40,127	153,714		123,859
Unrecognized expense	193,573	[2]	'	193,573	[2]	'
Weighted Average Amortization Period (Years)	'		'	'1 year 9 months 18 days		'
General and administrative	'		'	'		'
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]	'		'	'		'
Stock-based compensation expense	21,280		52,681	104,979		106,431
Unrecognized expense	$151,659		'	$151,659		'
Weighted Average Amortization Period (Years)	'		'	'1 year 7 months 6 days		'
[1]	Includes $8,363 of unrecognized expense that is subject to non-employee mark-to-market adjustments.
[2]	Includes $152,710 of unrecognized expense that is subject to non-employee mark-to-market adjustments.

Summary_of_Stock_Option_Activi

Summary of Stock Option Activity (Detail) (USD $)	6 Months Ended
	Jun. 30, 2014
Number of Options	'
Outstanding	5,043,000
Granted	3,700,000
Exercised	0
Forfeited	-34,000
Outstanding	8,709,000
Exercisable	5,323,167
Weighted Average Exercise Price	'
Outstanding	$1.03
Granted	$0.55
Exercised	$0
Forfeited	$1.31
Outstanding	$0.83
Exercisable	$0.97
Weighted Average Remaining Life In Years	'
Outstanding	'8 years 4 months 24 days
Exercisable	'7 years 4 months 24 days
Intrinsic Value	'
Outstanding	$13,500
Exercisable	$3,000

Information_Related_to_Stock_O1

Information Related to Stock Options (Detail) (USD $)	6 Months Ended
	Jun. 30, 2014
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]	'
Options Outstanding, Number of Options	8,709,000
Options Exercisable, Weighted Average Remaining Life In Years	'7 years 4 months 24 days
Options Exercisable, Exercisable Number of Options	5,323,167
Exercise Price 1	'
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]	'
Options Outstanding, Exercise Price	0.285
Options Outstanding, Number of Options	900,000
Options Exercisable, Weighted Average Remaining Life In Years	'10 years
Options Exercisable, Exercisable Number of Options	200,000
Exercise Price 2	'
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]	'
Options Outstanding, Exercise Price	0.39
Options Outstanding, Number of Options	60,000
Options Exercisable, Weighted Average Remaining Life In Years	'0 years
Options Exercisable, Exercisable Number of Options	0
Exercise Price 3	'
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]	'
Options Outstanding, Exercise Price	0.5
Options Outstanding, Number of Options	345,000
Options Exercisable, Weighted Average Remaining Life In Years	'5 years 4 months 24 days
Options Exercisable, Exercisable Number of Options	332,500
Exercise Price 4	'
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]	'
Options Outstanding, Exercise Price	0.53
Options Outstanding, Number of Options	40,000
Options Exercisable, Weighted Average Remaining Life In Years	'9 years 8 months 12 days
Options Exercisable, Exercisable Number of Options	40,000
Exercise Price 5	'
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]	'
Options Outstanding, Exercise Price	0.6
Options Outstanding, Number of Options	980,000
Options Exercisable, Weighted Average Remaining Life In Years	'9 years 3 months 18 days
Options Exercisable, Exercisable Number of Options	490,000
Exercise Price 6	'
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]	'
Options Outstanding, Exercise Price	0.65
Options Outstanding, Number of Options	2,675,000
Options Exercisable, Weighted Average Remaining Life In Years	'5 years 7 months 6 days
Options Exercisable, Exercisable Number of Options	791,667
Exercise Price 7	'
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]	'
Options Outstanding, Exercise Price	1
Options Outstanding, Number of Options	131,000
Options Exercisable, Weighted Average Remaining Life In Years	'8 years 1 month 6 days
Options Exercisable, Exercisable Number of Options	81,000
Exercise Price 8	'
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]	'
Options Outstanding, Exercise Price	1.05
Options Outstanding, Number of Options	2,270,000
Options Exercisable, Weighted Average Remaining Life In Years	'7 years 7 months 6 days
Options Exercisable, Exercisable Number of Options	2,270,000
Exercise Price 9	'
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]	'
Options Outstanding, Exercise Price	1.1
Options Outstanding, Number of Options	5,000
Options Exercisable, Weighted Average Remaining Life In Years	'2 years 10 months 24 days
Options Exercisable, Exercisable Number of Options	5,000
Exercise price 10	'
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]	'
Options Outstanding, Exercise Price	1.2
Options Outstanding, Number of Options	10,000
Options Exercisable, Weighted Average Remaining Life In Years	'1 year 10 months 24 days
Options Exercisable, Exercisable Number of Options	10,000
Exercise Price 11	'
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]	'
Options Outstanding, Exercise Price	1.25
Options Outstanding, Number of Options	43,000
Options Exercisable, Weighted Average Remaining Life In Years	'2 years 4 months 24 days
Options Exercisable, Exercisable Number of Options	43,000
Exercise Price 12	'
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]	'
Options Outstanding, Exercise Price	1.4
Options Outstanding, Number of Options	350,000
Options Exercisable, Weighted Average Remaining Life In Years	'5 years 4 months 24 days
Options Exercisable, Exercisable Number of Options	160,000
Exercise Price 13	'
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]	'
Options Outstanding, Exercise Price	1.5
Options Outstanding, Number of Options	900,000
Options Exercisable, Weighted Average Remaining Life In Years	'8 years 4 months 24 days
Options Exercisable, Exercisable Number of Options	900,000

Information_Related_to_Common_

Information Related to Common Stock Award Expense (Detail) (Common Stock Award, USD $)	3 Months Ended		6 Months Ended
	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]	'	'	'	'
Stock-based compensation expense	$226,327	$6,001	$240,398	$54,724
Unrecognized expense	0	'	0	'
Consulting	'	'	'	'
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]	'	'	'	'
Stock-based compensation expense	224,500	6,001	234,500	54,001
Unrecognized expense	0	'	0	'
Research and development	'	'	'	'
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]	'	'	'	'
Stock-based compensation expense	1,827	0	5,898	723
Unrecognized expense	0	'	0	'
General and administrative	'	'	'	'
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]	'	'	'	'
Stock-based compensation expense	0	0	0	0
Unrecognized expense	$0	'	$0	'

Summary_of_Common_Stock_Award_

Summary of Common Stock Award Activity (Detail) (Common Stock Award, USD $)	6 Months Ended
	Jun. 30, 2014
Common Stock Award	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'
Number of Shares, Beginning Balance	0
Number of Shares, Granted	878,458
Number of Shares, Vested	-878,458
Number of Shares, Forfeited	0
Number of Shares, Ending Balance	0
Weighted Average Grant Date Fair Value, Beginning Balance	$0
Weighted Average Grant Date Fair Value, Granted	$0.27
Weighted Average Grant Date Fair Value, Vested	($0.27)
Weighted Average Grant Date Fair Value, Forfeited	$0
Weighted Average Grant Date Fair Value, Ending Balance	$0
Total Grant Date Fair Value, Beginning Balance	$0
Total Grant Date Fair Value, Granted	240,398
Total Grant Date Fair Value, Vested	-240,398
Total Grant Date Fair Value, Forfeited	0
Total Grant Date Fair Value, Ending Balance	$0

Subsequent_Events_Additional_I

Subsequent Events- Additional Information (Detail) (USD $)

3 Months Ended

6 Months Ended

6 Months Ended

1 Months Ended

0 Months Ended

6 Months Ended

1 Months Ended

Jun. 30, 2014

Jun. 30, 2013

Jun. 30, 2014

Jun. 30, 2013

Jun. 30, 2014

Jun. 30, 2014

Jun. 30, 2014

Jun. 30, 2014

Jun. 30, 2014

Jun. 30, 2014

Jun. 30, 2014

Jun. 30, 2014

Jun. 30, 2014

Jun. 30, 2014

Feb. 20, 2014

Mar. 14, 2014

Jun. 30, 2014

Aug. 13, 2014

Jul. 31, 2014

8-May-14

Jul. 23, 2014

Common Stock And Warrant Offerings [Member]

Maximum [Member]

Maximum [Member]

Minimum [Member]

Minimum [Member]

Consultant

Convertible Notes Payable

Notes Payable, Other Payables [Member]

Notes Payable

Notes Payable, Accrued Interest Exchanged [Member]

Chief Medical Advisor [Member]

Scientific Advisory Board [Member]

Consultant Agreement

Subsequent Event

Subsequent Event

Subsequent Event

Subsequent Event

Common Stock And Warrant Offerings [Member]

Common Stock And Warrant Offerings [Member]

Consultant

Subsequent Event [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Research and Development Expense

$293,330

$372,916

$787,071

$773,358

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$89,063

'

'

Long-term Debt, Gross

'

'

'

'

'

'

'

'

'

'

'

'

76,669

'

'

'

'

4,000,000

'

'

'

Stock Issued During Period, Shares, New Issues

'

'

'

'

703,333

'

'

'

'

10,000

'

'

'

'

'

'

45,273

550,000

'

'

30,000

Sale of Stock, Price Per Share

'

'

'

'

'

$0.45

$0.30

$0.25

$0.25

'

'

'

'

'

'

'

'

'

'

'

'

Debt Conversion, Converted Instrument, Shares Issued

'

'

'

'

'

'

'

'

'

'

'

'

489,505

'

'

'

'

'

'

'

'

Proceeds from Issuance of Common Stock

'

'

80,000

'

205,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Warrants To Purchase Shares Of Common Stock

'

'

'

'

175,833

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Class of Warrant or Right, Exercise Price of Warrants or Rights

$0.75

'

$0.75

'

$0.75

$2.50

'

$1.75

'

'

'

'

'

'

'

'

'

'

'

'

'

Share-Based Compensation Arrangements By Share-Based Payment Award, Options, Grants In Period, Weighted Average Exercise Price

'

'

$0.55

'

'

'

'

'

'

$0.75

'

'

'

'

$0.65

$0.50

'

'

'

'

'

Prepayment Of Debt

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

89,063

'

Note accrued interest converted to equity

'

'

($274,000)

'

'

'

'

'

'

'

($71,000)

($203,000)

'

$2,992

'

'

'

'

'

'

'